

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 January 2002 (17.01.2002)

PCT

(10) International Publication Number
WO 02/04616 A1

(51) International Patent Classification⁷: **C12N 9/24**,
A61K 38/47, A61P 3/00

[US/US]; 371 Bel Marin Keys Boulevard, Suite 210, Novato, CA 94949 (US). **STARR, Christopher, M.** [US/US]; 371 Bel Marin Keys Boulevard, Suite 210, Novato, CA 94949 (US). **KAKKIS, Emil, D.** [US/US]; 345 Willow Road, Nicasio, CA 94946 (US).

(21) International Application Number: PCT/US00/31293

(22) International Filing Date:
9 November 2000 (09.11.2000)

(74) Agent: **HALLUIN, Albert, P.**; Howrey Simon Arnold & White, LLP, Box 34, 301 Ravenswood Avenue, Menlo Park, California 94025 (US).

(25) Filing Language: English

(26) Publication Language: English

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(30) Priority Data:
Not furnished 12 November 1999 (12.11.1999)

(71) Applicants (*for all designated States except US*): **BIOMARIN PHARMACEUTICALS** [US/US]; Suite 210, 371 Bel Marin Keys Boulevard, Novato, CA 94949 (US). **HARBOR-UCLA RESEARCH AND EDUCATION INSTITUTE** [US/US]; 1124 West Carson Street, Torrance, CA 90502 (US).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant and
(72) Inventor: **HENDSTRAND, John, M.** [—/US]; 371 Bel Marin Keys Boulevard, Suite 210, Novato, CA 94949 (US).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

(72) Inventors; and
(75) Inventors/Applicants (*for US only*): **QIN, Minmin** [US/US]; Suite 210, 371 Bel Marin Keys Boulevard, Novato, CA 94949 (US). **CHAN, Wia-Pan** [US/US]; Suite 210, 371 Bel Marin Keys Boulevard, Navoto, CA 94949 (US). **CHEN, Lin** [CN/US]; 371 Bel Marin Keys Boulevard, Suite 210, Novato, CA 94949 (US). **FITZPATRICK, Paul, A.** [US/US]; 371 Bel Marin Keys Boulevard, Suite 210, Novato, CA 94949 (US). **WENDT, Dan, J.** [US/US]; 371 Bel Marin Keys Boulevard, Suite 210, Novato, CA 94949 (US). **ZECHERLE, Gary, N.**

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: RECOMBINANT α -L-IDURONIDASE, METHODS FOR PRODUCING AND PURIFYING THE SAME AND METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES THEREOF

(57) Abstract: The present invention provides a recombinant human α -L-iduronidase and biologically active fragments and mutants thereof, large scale methods to produce and purify commercial grade recombinant human α -L-iduronidase enzyme as well as methods to treat certain genetic disorders including α -L-iduronidase deficiency and mucopolysaccharidosis I (MPS 1).



WO 02/04616 A1

RECOMBINANT α -L-IDURONIDASE, METHODS FOR
PRODUCING AND PURIFYING THE SAME AND METHODS
FOR TREATING DISEASES CAUSED BY DEFICIENCIES THEREOF

FIELD OF THE INVENTION

5 The present invention is in the field of molecular biology, enzymology,
biochemistry and clinical medicine. In particular, the present invention provides a human
recombinant α -L-iduronidase, methods of large-scale production and purification of
commercial grade human recombinant α -L-iduronidase enzyme, and methods to treat
certain genetic disorders including α -L-iduronidase deficiency and
10 mucopolysaccharidosis I (MPS I).

BACKGROUND OF THE INVENTION

Carbohydrates play a number of important roles in the functioning of living
organisms. In addition to their metabolic roles, carbohydrates are structural components
15 of the human body covalently attached to numerous other entities such as proteins and
lipids (called glycoconjugates). For example, human connective tissues and cell
membranes comprise proteins, carbohydrates and a proteoglycan matrix. The
carbohydrate portion of this proteoglycan matrix provides important properties to the
body's structure.

20 A genetic deficiency of the carbohydrate-cleaving, lysosomal enzyme α -L-
iduronidase causes a lysosomal storage disorder known as mucopolysaccharidosis I (MPS
I) (Neufeld and Muenzer, pp. 1565-1587, in *The Metabolic Basis of Inherited Disease*,
Eds., C.R. Scriver, A.L. Beaudet, W.S. Sly, and D.Valle, McGraw-Hill, New York
(1989)) In a severe form, MPS I is commonly known as Hurler syndrome and is
25 associated with multiple problems such as mental retardation, clouding of the cornea,
coarsened facial features, cardiac disease, respiratory disease, liver and spleen
enlargement, hernias, and joint stiffness. Patients suffering from Hurler syndrome usually
die before age 10. In an intermediate form known as Hurler-Scheie syndrome, mental
function is generally not severely affected, but physical problems may lead to death by
30 the teens or twenties. Scheie syndrome is the mildest form of MPS I. It is compatible
with a normal life span, but joint stiffness, corneal clouding and heart valve disease cause
significant problems.

The frequency of MPS I is estimated to be 1:100,000 according to a British Columbia survey of all newborns (Lowry, *et al.*, *Human Genetics* 85:389-390 (1990)) and 1:70,000 according to an Irish study (Nelson, *Human Genetics* 101:355-358 (1990)). There appears to be no ethnic predilection for this disease. It is likely that worldwide the disease is underdiagnosed either because the patient dies of a complication before the diagnosis is made or because the milder forms of the syndrome may be mistaken for arthritis or missed entirely. Effective newborn screening for MPS I would likely find some previously undetected patients.

Except for a few patients which qualify for bone marrow transplantation, there are no significant therapies available for all MPS I patients. Hobbs, *et al.* (*Lancet* 2: 709-712 (1981)) first reported that bone marrow transplantation successfully treated a Hurler patient. Since that time, clinical studies at several transplant centers have shown improvement in physical disease and slowing or stabilizing of developmental decline if performed early. (Whitley, *et al.*, *Am. J. Med. Genet.* 46: 209-218 (1993); Vellodi, *et al.*, *Arch. Dis. Child.* 76: 92-99 (1997); Peters, *et al.*, *Blood* 91: 2601-2608 (1998); Guffon, *et al.*, *J. Pediatrics* 133: 119-125 (1998)) However, the significant morbidity and mortality, and the need for matched donor marrow, limits the utility of bone marrow transplants. An alternative therapy available to all affected patients would provide an important breakthrough in treating and managing this disease.

Enzyme replacement therapy has been considered a potential therapy for MPS I following the discovery that α -L-iduronidase can correct the enzymatic defect in Hurler cells in culture, but the development of human therapy has been technically unfeasible until now. In the corrective process, the enzyme containing a mannose-6-phosphate residue is taken up into cells through receptor-mediated endocytosis and transported to the lysosomes where it clears the stored substrates, heparan sulfate and dermatan sulfate. Application of this therapy to humans has previously not been possible due to inadequate sources of α -L-iduronidase in tissues.

For α -L-iduronidase enzyme therapy in MPS I, a recombinant source of enzyme has been needed in order to obtain therapeutically sufficient supplies of the enzyme. The cDNA for the canine enzyme was cloned in 1991 (Stoltzfus, *et al.*, *J. Biol. Chem.* 267:6570-6575 (1992)) and for the human enzyme in the same year. (Scott, *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 88:9695-9699 (1991), Moskowitz, *et al.*, *FASEB J* 6:A77 (1992)). Following the cloning of cDNA for α -L-iduronidase, the production of adequate

quantities of recombinant α -L-iduronidase allowed the study of enzyme replacement therapy in canine MPS I. (Kakkis, *et al.*, *Protein Expr. Purif.* 5: 225-232 (1994)) Enzyme replacement studies in the canine MPS I model demonstrated that intravenously-administered recombinant α -L-iduronidase distributed widely and reduced lysosomal storage from many tissues. (Shull, *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 91: 12937-12941 (1994); Kakkis, *et al.*, *Biochem. Mol. Med.* 58: 156-167 (1996))

BRIEF SUMMARY OF THE INVENTION

In one aspect, the present invention features a method to mass produce human recombinant α -L-iduronidase in large scale amounts with appropriate purity to enable large scale production for long term patient use of the enzyme therapy. In a broad embodiment, the method comprises the step of transfecting a cDNA encoding for all or part of an α -L-iduronidase into a cell suitable for the expression thereof. In some embodiments, a cDNA encoding for a complete α -L-iduronidase is used, preferably a human α -L-iduronidase. However, in other embodiments, a cDNA encoding for a biologically active fragment or mutant thereof may be used. Specifically, one or more amino acid substitutions may be made while preserving or enhancing the biological activity of the enzyme. In other preferred embodiments, an expression vector is used to transfer the cDNA into a suitable cell or cell line for expression thereof. In one particularly preferred embodiment, the cDNA is transfected into a Chinese hamster ovary cell to create cell line 2.131. In yet other preferred embodiments, the production procedure features one or more of the following characteristics which have demonstrated particularly high production levels: (a) the pH of the cell growth culture may be lowered to about 6.5 to 7.0, preferably to about 6.8 - 7.0 during the production process, (b) as many as 2 to 3.5 culture volumes of the medium may be changed during each 24-hour period by continuous perfusion, (c) oxygen saturation may be optimized to about 40% but may be as high as 80%, (d) macroporous cellulose microcarriers with about 5% serum in the medium initially, may be used to produce cell mass followed by a rapid washout shift to protein-free medium for production, (e) a protein-free or low protein-medium such as a JRH Biosciences PF-CHO product may be optimized to include supplemental amounts of one or more ingredients selected from the group consisting of: glutamate, aspartate, glycine, ribonucleosides, and deoxyribonucleosides; (f) a stirred tank suspension culture may be perfused in a continuous process to produce iduronidase.

In a second aspect, the present invention provides a transfected cell line which features the ability to produce α -L-iduronidase in amounts which enable using the enzyme therapeutically. In preferred embodiments, the present invention features a recombinant Chinese hamster ovary cell line such as the 2.131 cell line that stably and reliably produces amounts of α -L-iduronidase which enable using the enzyme therapeutically. In some preferred embodiments, the cell line may contain more than 1 copy of an expression construct. In even more preferred embodiments, the cell line expresses recombinant α -L-iduronidase in amounts of at least 20 micrograms per 10^7 cells per day.

10 In a third aspect, the present invention provides novel vectors suitable to produce α -L-iduronidase in amounts which enable using the enzyme therapeutically. In preferred embodiments, the present invention features an expression vector comprising a cytomegalovirus promoter/enhancer element, a 5' intron consisting of a murine C α intron, a cDNA encoding all or a fragment or mutant of an α -L-iduronidase, and a 3' bovine growth hormone polyadenylation site. Also, preferably the cDNA encoding all or a fragment or mutant of an α -L-iduronidase is about 2.2 kb in length. This expression vector may be transfected at, for example, a 50 to 1 ratio with any appropriate common selection vector such as pSV2NEO, to enhance multiple copy insertions. Alternatively, gene amplification may be used to induce multiple copy insertions.

20 In a fourth aspect, the present invention provides novel α -L-iduronidase produced in accordance with the methods of the present invention and thereby present in amounts which enable using the enzyme therapeutically. The specific activity of the α -L-iduronidase according to the present invention is in excess of 200,000 units per milligram protein. Preferably, it is in excess of about 240,000 units per milligram protein. The molecular weight of the α -L-iduronidase of the present invention is about 82,000 daltons, about 70,000 daltons being amino acid, and about 12,000 daltons being carbohydrates.

25 In a fifth aspect, the present invention features a novel method to purify α -L-iduronidase. According to a first embodiment, a cell mass may be grown in about 5% serum-containing medium, followed by a switch to a modified protein-free production medium without any significant adaptation to produce a high specific activity starting material for purification. In one preferred embodiment, a three step column chromatography may be used to purify the enzyme. Such a three step column chromatography may include using a blue sepharose FF, a Cu⁺⁺ chelating sepharose

chromatography and a phenyl sepharose HP chromatography. In another preferred embodiment, an acid pH treatment step is used to inactivate potential viruses without harming the enzyme. Concanavalin A-Sepharose, Heparin-Sepharose and Sephacryl 200 columns are removed and Blue-Sepharose and copper chelating columns added to
5 increase the capacity of the large scale purification process, to reduce undesirable leachables inappropriate for long term patient use, and to improve the purity of the product.

In a sixth aspect, the present invention features novel methods of treating diseases caused all or in part by a deficiency in α -L-iduronidase. In one embodiment, this method
10 features administering a recombinant α -L-iduronidase or a biologically active fragment or mutant thereof alone or in combination with a pharmaceutically suitable carrier. In other embodiments, this method features transferring a nucleic acid encoding all or a part of an α -L-iduronidase into one or more host cells *in vivo*. Preferred embodiments include optimizing the dosage to the needs of the organism to be treated, preferably mammals or
15 humans, to effectively ameliorate the disease symptoms. In preferred embodiments, the disease is Mucopolysaccharidosis I (MPS I), Hurler syndrome, Hurler-Scheie syndrome or Scheie syndrome.

In a seventh aspect, the present invention features novel pharmaceutical compositions comprising α -L-iduronidase useful for treating a disease caused all or in
20 part by a deficiency in α -L-iduronidase. Such compositions may be suitable for administration in a number of ways such as parenteral, topical, intranasal, inhalation or oral administration. Within the scope of this aspect are embodiments featuring nucleic acid sequences encoding all or a part of an α -L-iduronidase which may be administered *in vivo* into cells affected with an α -L-iduronidase deficiency.

25

DESCRIPTION OF THE FIGURES

FIGURE 1 represents the nucleotide and deduced amino acid sequences of cDNA encoding α -L-iduronidase (SEQ ID NOs:1 and 2). Nucleotides 1 through 6200 are
30 provided. Amino acids are provided starting with the first methionine in the open reading frame.

FIGURE 2 represents the results from SDS-PAGE runs of eluate obtained according to the procedures as described below. The top panel shows the SDS-PAGE

results of purified α -L-iduronidase (3 micrograms) and contaminants from the production/purification scheme disclosed in Kakkis, *et al.*, *Protein Expr. Purif.* 5: 225-232 (1994). In the bottom panel, SDS-PAGE results of purified α -L-iduronidase with contaminants from an unpublished prior production/purification process (U.S. Patent
5 Application Serial Nos. 09/078,209 and 09/170,977) referred to as the Carson method in Lanes 2 (7.5 microgram α -L-iduronidase) and Lane 3 (5.0 microgram α -L-iduronidase) are compared to that of the production/purification process of the present invention referred to as the Galli Process (Lane 4 5 micrograms α -L-iduronidase). Lane 1 contains the molecular weight marker. FIGURE 2 shows that the Galli production/purification
10 method of the present invention yields a highly purified α -L-iduronidase product with fewer contaminants in comparison with prior production/purification schemes.

FIGURE 3 demonstrates the α -iduronidase production level over a 30-day period, during which time cells are switched at day 5 from a serum – containing medium to a serum-free medium. α -Iduronidase production was characterized by: (1) absence of a
15 need for adaptation when cells are switched from serum-containing to serum-free medium at 100200 (top and bottom panels) with an uninterrupted increase in productivity (top panel); (2) a high level of production in excess of 4 mg per liter (1000 per mL) in a protein-free medium (bottom panel); and (3) a boost in α -iduronidase production with butyrate induction events (bottom panel).

20 FIGURE 4 demonstrates a decrease in liver volume during enzyme therapy in MPS I patients.

FIGURE 5 demonstrates urinary GAG excretion during enzyme therapy.

FIGURE 6 demonstrates elbow and knee extension in HAC002 during enzyme therapy.

25 FIGURE 7 demonstrates shoulder flexion to 104 weeks in four patients with the most restriction during enzyme therapy.

FIGURE 8 demonstrates improvement in sleep apnea before and after six weeks of therapy.

30 FIGURE 9 demonstrates the improvement in apneas and hypopneas during sleep with enzyme therapy in each individual patient.

FIGURE 10 demonstrates the improvement in pulmonary function tests before and after 12 and 52 weeks of enzyme therapy in one patient.

FIGURE 11 demonstrates increased height growth velocity with enzyme therapy.

FIGURE 12 shows the degree of contamination by Chinese Hamster Ovary Protein (CHOP) and degree of purity of α -L-iduronidase, produced by (1) the Carson method, an unpublished prior production/purification process (U.S. Patent Application Serial Nos. 09/078,209 and 09/170,977 and (2) the Galli method, the
5 production/purification process of the present invention. Thus, FIGURE 12 shows that α -L-iduronidase produced and purified by the Galli method has a higher degree of purity and lower degree of CHOP contamination in comparison to that of the Carson method.

DETAILED DESCRIPTION OF THE INVENTION

10 In one aspect, the present invention features a method to produce α -L-iduronidase in amounts which enable using the enzyme therapeutically. In general, the method features transforming a suitable cell line with the cDNA encoding for all of α -L-iduronidase or a biologically active fragment or mutant thereof. Those of skill in the art may prepare expression constructs other than those expressly described herein for optimal
15 production of α -L-iduronidase in suitable cell lines transfected therewith. Moreover, skilled artisans may easily design fragments of cDNA encoding biologically active fragments and mutants of the naturally occurring α -L-iduronidase which possess the same or similar biological activity to the naturally occurring full-length enzyme.

To create a recombinant source for α -L-iduronidase, a large series of expression
20 vectors may be constructed and tested for expression of a α -L-iduronidase cDNA. Based on transient transfection experiments, as well as stable transfections, an expression construct may be identified that provides a particularly high level of expression. In one embodiment of the present invention, a Chinese hamster cell line 2.131 developed by transfection of the α -L-iduronidase expression construct and selection for a high
25 expression clone provides particularly high level expression. Such a Chinese hamster cell line according to this embodiment of the present invention may secrete about 5,000 to 7,000 fold more α -L-iduronidase than normal. The α -L-iduronidase produced thereby may be properly processed, taken up into cells with high affinity and is corrective for α -L-iduronidase deficient cells, such as those from patients suffering from Hurler's
30 Syndrome.

The method for producing α -L-iduronidase in amounts that enable using the enzyme therapeutically features a production process specifically designed to mass

produce commercial grade enzyme, wherein the quality of the enzyme has been deemed acceptable for administration to humans by regulatory authorities of various countries. The large scale production of commercial grade enzyme necessitates modifications of the cell culture scale, microcarrier systems, and purification scheme. In preferred
5 embodiments, the cell culture scale is increased from 45 liters to 110 liters or more, with a change to continuous perfusion. The increase in scale is necessary to produce sufficient material for potential large scale production for long term patient use. According to preferred embodiments of such a process, microcarriers are used as a low cost scalable surface on which to grow adherent cells. In particularly preferred embodiments, such
10 microcarriers are macroporous and are specifically composed of modified carbohydrates such as cellulose, e.g., Cytopore beads manufactured by Pharmacia. Macroporous cellulose microcarriers allow improved cell attachment and provide a larger surface area for attachment, which is expected to yield an increased cell density during the culture process. Higher cell densities are expected to increase productivity. In preferred
15 embodiments, heparin-Sepharose and Sephacryl 200 columns are replaced with Blue-Sepharose and Copper chelating columns to increase the capacity of the large scale purification process and to improve the purity of the product. In a particularly preferred embodiment, the copper chelating column is used to reduce Chinese hamster ovary cell protein contaminants to very low levels appropriate for large scale distribution. Using
20 embodiments of the present method featuring modifications and induction described below, approximately 15 mg per liter of culture per day, or more at peak culturing density can be produced starting with a 110 liter culture system.

According to other preferred embodiments of the method for producing α -L-iduronidase according to the present invention, a culture system is optimized. In a first
25 embodiment, the culture pH is lowered to about 6.5 to 7.0, preferably to about 6.7-7.0 during the production process. One advantage of such a pH is to enhance accumulation of lysosomal enzymes that are more stable at acidic pH. In a second embodiment, as many as 2 to 3.5 culture volumes of the medium may be changed during each 24-hour period by continuous perfusion. One advantage of this procedure is to enhance the
30 secretion rate of recombinant α -L-iduronidase and to capture more active enzyme. In a third embodiment, oxygen saturation is optimized at about 40%. In a fourth embodiment, macroporous microcarriers with about 5% serum initially in the medium, are used to produce a cell mass followed by a rapid washout shift to a protein-free medium for production (FIGURE 3). In a fifth embodiment, a protein-free growth medium, such as a

JRH Biosciences PF-CHO product, may be optimized to include supplemental amounts of one or more ingredients selected from the group consisting of: glutamate, aspartate, glycine, ribonucleosides and deoxyribonucleosides. In a sixth embodiment, as many as 2 to 3.5 culture volumes of the medium may be changed during each 24-hour period by continuous perfusion. Such an induction process may provide about a two-fold increase in production without significantly altering post-translational processing.

Particularly preferred embodiments of the method for producing α -L-iduronidase according to the present invention feature one, more than one, or all of the optimizations described herein and may be employed as described in more detail below. The production method of the present invention may, therefore, provide a production culture process having the following features:

1. A microcarrier based culture using macroporous microcarrier beads made of modified cellulose or an equivalent thereof is preferably used in large scale culture flasks with overhead stirring or an equivalent thereof. Attachment of cells to these beads may be achieved by culture in a 5% fetal bovine serum may be added to DME/F12 1:1 or a protein-free medium modified with ingredients including ribonucleosides, deoxyribonucleosides, pyruvate, non-essential amino acids, and HEPES. After about 3-6 days in this medium, a washout procedure is begun in which protein-free medium replaces the serum-containing medium at an increasing perfusion rate dependent on the glucose content and culture condition. Subsequently, and throughout the entire remaining culture period, the cells are cultivated in a protein-free medium. The use of a protein-free medium in enzyme production is beneficial in reducing the exposure risk of bovine spongiform encephalopathy (BSE) and other infectious biologic agents such as viruses to patients being treated with the enzyme, wherein the risk of BSE or other harmful agents is dependent on the amount of potential serum exposure. In prior published studies, the carriers used to grow the cells were bovine gelatin microcarriers, used at 1 gram per liter or 100 times the product concentration. Leaching of 1% of the gelatin protein from the microcarriers would represent a relative 100% contamination and thereby contribute to the risk of BSE. Thus, new carriers are either dextran or cellulose-based and consist of carbohydrates, and not animal-derived materials.

FIGURE 3 shows that the cells are grown to a density in 5% serum containing medium and then switched without any adaptation to a protein-free medium. FIGURE 3 specifically shows that: 1) Cells survive and continue to produce iduronidase when shifted without adaptation. In contrast, other studies would suggest that adaptation to a

protein-free medium is necessary. In the method of the present invention, enzyme production continues at levels comparable to serum containing medium. 2) α -L-Iduronidase produced in a protein-free medium retains a level of production in excess of 4 mg per liter or 1,000 units per ml. 3) α -L-Iduronidase produced in a protein-free medium has high uptake indicating that the shift in medium and, hence, a shift in carbohydrates being fed to cells, does not adversely affect the high uptake character of the enzyme. Eight lots of α -L-iduronidase have been produced and released in this manner with an uptake half maximal value of less than 2nM in all lots.

2. The culture conditions are preferably maintained at a dissolved oxygen of 40% of air saturation at a pH of about 6.8-7.0 and at a temperature of about 35-37° C. This may be achieved using a control unit, monitoring unit and appropriate probes such as those produced by Applikon® or Mettler®. However, skilled artisans will readily appreciate that this can easily be achieved by equivalent control systems produced by other manufacturers. An air saturation of about 40% results in improved α -L-iduronidase secretion though up to 80%% air saturation may be used. However, further increases in oxygen to, for example, 90% air saturation, do not provide significantly enhanced secretion over 80% air saturation. The dissolved oxygen may be supplied by intermittent or continuous oxygen sparging using a 5 micron stainless steel or larger opening sparger, or equivalent thereof. A pH of about 6.8-7.0 is optimal for the accumulation of the α -L-iduronidase enzyme. The enzyme is particularly unstable at pHs above about 7.0. Below a pH of about 6.7, the secretion rate may decrease, particularly below a pH of about 6.5. The culture is therefore maintained optimally between a pH of about 6.8-7.0 .

3. The production culture medium may be a modified form of the commercially available proprietary medium from JRH Biosciences called Excell PF CHO. This medium supports levels of secretion equivalent to that of serum using a cell line such as the 2.131 cell line. It may be preferably modified to include an acidic pH of about 6.8-7.0 (\pm 0. 1), and buffered with HEPES at 7.5 mM or 15 mM. The medium may contain 0.05 to 0.1% of Pluronic F-68 (BASF), a non-ionic surfactant or an equivalent thereof which features the advantage of protecting cells from shear forces associated with sparging. The medium may further contain a proprietary supplement that is important in increasing the productivity of the medium over other protein-free media that are presently available. Those skilled in the art will readily understand that the choice of culture medium may be optimized continually according to particular commercial embodiments

available at particular points in time. Such changes encompass no more than routine experimentation and are intended to be within the scope of the present invention.

4. The production medium may be analyzed using an amino acid analyzer comparing spent medium with starting medium. Such analyses have demonstrated that
5 the 2.131 cell line depletes a standard PF CHO medium of glycine, glutamate and aspartate to a level of around 10% of the starting concentration. Supplementation of these amino acids to higher levels may result in enhanced culture density and productivity that may lead to a 2-3 fold higher production than at baseline. Skilled artisans will appreciate that other cell lines within the scope of the present invention may be equally useful for
10 producing α -L-iduronidase according to the present method. Hence, more or less supplemental nutrients may be required to optimize the medium. Such optimizations are intended to be within the scope of the present invention and may be practiced without undue experimentation.

5. The medium may be supplemented with the four ribonucleosides and four
15 deoxyribonucleosides each at about 10 mg/liter to support the dihydrofolate reductase deficient cell line 2.131. Skilled artisans will appreciate that other cell lines within the scope of the present invention may be equally useful for producing α -L-iduronidase according to the present method. Hence, more or less ribonucleosides and deoxyribonucleosides may be required to optimize the medium, and alternative sources of
20 purines and pyrimidines for nucleic acid synthesis may be used such as hypoxanthine and thymidine. Such optimizations are intended within the scope of the present invention and may be practiced without undue experimentation.

6. After reaching confluence at about 3-6 days of culture, an increasing rate of continuous perfusion is initiated. A change of medium may be accomplished, for
25 example, using a slant feed tube constructed and positioned to allow the uptake of medium without removal of the microcarriers even while the culture is stirred. By pumping out medium through the slant feed tube, microcarriers settle within the body of the tube inside the culture and are not removed from the culture during the change on medium. In this manner, the microcarriers with the cell mass are separated from
30 supernatant containing the enzyme.

7. The rapid and frequent turnover of the medium has been shown by productivity studies to result in improved overall collection of enzyme from the cell culture. Less turnover of medium results in less total production of enzyme on a daily

basis. Using the perfusion of 2-3.5 culture volumes per day, the cells may be maintained in excellent condition with high degrees of viability and a high level of productivity.

8. Production of α -L-iduronidase may be enhanced by the use of sodium butyrate induction of gene expression (FIGURE 3). Twenty lots of α -L-iduronidase were produced using butyrate induction at 2mM concentration with 2/3 washout every 12 hours after induction and reinduction every 48 hours for a 21-day production period. In Figure 3, the vertical arrows at the bottom indicate butyrate induction events. Each induction triggered a boost in α -L-iduronidase concentration in the medium.

Systematic studies of a 2.131 cell line demonstrated that about 2 mM butyrate can be applied and result in about a two-fold or greater induction of enzyme production with minimal effects on carbohydrate processing. Lower levels of butyrate have not been shown to induce as well, and substantially higher levels may result in higher induction, but declining affinity of the produced enzyme for cells from patients suffering from α -L-iduronidase deficiency. Butyrate induction performed *in vitro* at 2mM for 24 hours or 5 mM, a more commonly used concentration resulted in uptakes in excess of 3 nM or 40 U/ml, or an average of three times the value observed in production lots. In addition, commonly used times of 24 hours or more and concentration of 5 mM were toxic to α -L-iduronidase producing cells and resulted in detachment and loss of cell mass.

Results suggest that two-fold or greater induction results in less processing of the carbohydrates and less phosphate addition to the enzyme, as well as increasing toxicity. With respect to carbohydrate processing and the addition of phosphate groups, the importance of mannose-6-phosphate in enzyme replacement therapy is demonstrated by the observations that removal of the phosphate of two lysosomal enzymes, glucosidase and galactosamine 4-sulfatase leads to decreased uptake (Van der Ploeg, *et al.*, *J. Clin. Invest.* 87: 513-518 (1991); Crawley, *et al.*, *J. Clin. Invest.* 97: 1864-1873 (1996)). In addition, enzyme with low phosphate (Van Hove, *et al.*, *Proc. Natl. Acad. Sci. USA* 93: 65-70 (1996) requires 1,000 units per ml for uptake experiments (nearly 100 times used for iduronidase) and effective doses in animal models require 14 mg/kg, or 28 times the dose used with high phosphate containing iduronidase (Kikuchi, *et al.*, *J. Clin. Invest.* 101: 827-833 (1998)).

One particularly preferred aspect of the invention method uses 2 mM butyrate addition every 48 hours to the culture system. This embodiment results in about a two-

fold induction of enzyme production using this method without significant effect on the uptake affinity of the enzyme (K-uptake of less than 30 U/ml or 2.0 mM).

9. In a second aspect, the present invention provides a transfected cell line, which possesses the unique ability to produce α -L-iduronidase in amounts, which enable using the enzyme therapeutically. In preferred embodiments, the present invention features a recombinant Chinese hamster ovary cell line such as the 2.131 cell line that stably and reliably produces amounts of α -L-iduronidase. In preferred embodiments, the cell line may contain more than 1 copy of an expression construct comprising a CMV promoter, a C α intron, a human α -L-iduronidase cDNA, and a bovine growth hormone polyadenylation sequence. In even more preferred embodiments, the cell line expresses α -L-iduronidase at amounts of at least about 20-40 micrograms per 10^7 cells per day in a properly processed, high uptake form appropriate for enzyme replacement therapy. According to preferred embodiments of this aspect of the invention, the transfected cell line adapted to produce α -L-iduronidase in amounts which enable using the enzyme therapeutically, possesses one or more of the following features:

1. The cell line of preferred embodiments is derived from a parent cell line wherein the cells are passaged in culture until they have acquired a smaller size and more rapid growth rate and until they readily attach to substrates.
2. The cell line of preferred embodiments is transfected with an expression vector containing the cytomegalovirus promoter/enhancer element, a 5' intron consisting of the murine C α intron between exons 2 and 3, a human cDNA of about 2.2 kb in length, and a 3' bovine growth hormone polyadenylation site. This expression vector may be transfected at, for example, a 50 to 1 ratio with any appropriate common selection vector such as pSV2NEO. The selection vector pSV2NEO in turn confers G418 resistance on successfully transfected cells. In particularly preferred embodiments, a ratio of about 50 to 1 is used since this ratio enhances the acquisition of multiple copy number inserts. According to one embodiment wherein the Chinese hamster ovary cell line 2.131 is provided, there is at least 1 copy of the expression vector for α -L-iduronidase. Such a cell line has demonstrated the ability to produce large quantities of human α -L-iduronidase (minimum 20 micrograms per 10 million cells per day). Particularly preferred embodiments such as the 2.131 cell line possess the ability to produce properly processed enzyme that contains N-linked oligosaccharides containing high mannose

chains modified with phosphate at the 6 position in sufficient quantity to produce an enzyme with high affinity (K-uptake of less than 3 nM).

3. The enzyme produced from the cell lines of the present invention such as a Chinese hamster ovary cell line 2.131 is rapidly assimilated into cells, eliminates
5 glycosaminoglycan storage and has a half-life of about 5 days in cells from patients suffering from α -L-iduronidase deficiency.

4. The cell line of preferred embodiments such as a 2.131 cell line adapts to large scale culture and stably produces human α -L-iduronidase under these conditions. The cells of preferred embodiments are able to grow and secrete α -L-iduronidase at the
10 acid pH of about 6.6 to 7.0 at which enhanced accumulation of α -L-iduronidase can occur.

5. Particularly preferred embodiments of the cell line according to the invention, such as a 2.131 cell line are able to secrete human α -L-iduronidase at levels exceeding 2,000 units per ml (8 micrograms per ml) harvested twice per day or exceeding
15 15 mg per liter of culture per day using a specially formulated protein-free medium.

In a third aspect, the present invention provides novel vectors suitable to produce α -L-iduronidase in amounts which enable using the enzyme therapeutically. The production of adequate quantities of recombinant α -L-iduronidase is a critical prerequisite for studies on the structure of the enzyme as well as for enzyme replacement therapy.
20 The cell lines according to the present invention permit the production of significant quantities of recombinant α -L-iduronidase that is appropriately processed for uptake. Overexpression in Chinese hamster ovary (CHO) cells has been described for three other lysosomal enzymes, α -galactosidase (Ioannou, *et al.*, *J Cell. Biol.* 119:1137-1150 (1992)), iduronate 2-sulfatase (Bielicki, *et al.*, *Biochem. J.* 289: 241-246 (1993)), and N-acetylgalactosamine 4 -sulfatase (Amson, *et al.*, *Biochem. J.* 284:789-794 (1992)), using a
25 variety of promoters and, in one case, amplification. The present invention features a dihydrofolate reductase-deficient CHO cell line, but according to preferred embodiments of the invention amplification is unnecessary. Additionally, the present invention provides a high level of expression of the human α -L-iduronidase using the CMV
30 immediate early gene promoter/enhancer.

The present invention features in preferred embodiments, an expression vector comprising a cytomegalovirus promoter/enhancer element, a 5' intron consisting of the murine C α intron derived from the murine long chain immunoglobulin C α gene between

exons 2 and 3, a human cDNA of about 2.2 kb in length, and a 3' bovine growth hormone polyadenylation site. This expression vector may be transfected at, for example, a 50 to 1 ratio with any appropriate common selection vector such as pSV2NEO. The selection vector such as pSV2NEO in turn confers G418 resistance on successfully transfected
5 cells. In particularly preferred embodiments, a ratio of about 50 to 1 expression vector to selection vector is used since this ratio enhances the acquisition of multiple copy number inserts. According to one embodiment wherein the Chinese hamster ovary cell line 2.131 is provided, there are approximately 10 copies of the expression vector for α -L-iduronidase. Such an expression construct has demonstrated the ability to produce large
10 quantities of human α -L-iduronidase (minimum 20 micrograms per 10 million cells per day) in a suitable cell line such as a Chinese hamster ovary cell line 2.131.

In a fourth aspect, the present invention provides novel α -L-iduronidase produced in accordance with the methods of the present invention and thereby present in amounts that enable using the enzyme therapeutically. The methods of the present invention
15 produce a substantially pure α -L-iduronidase that is properly processed and in high uptake form, appropriate for enzyme replacement therapy and effective in therapy *in vivo*.

The specific activity of the α -L-iduronidase according to the present invention is in excess of about 200,000 units per milligram protein. Preferably, it is in excess of about 240,000 units per milligram protein using the original assay methods for activity and
20 protein concentration. A novel validated assay for the same enzyme with units expressed as micromoles per min demonstrates an activity of 100 units/ml (range of 70-130) and a protein concentration by absorbance at 280 nm of 0.7 mg/ml (0.6-0.8) with an average specific activity of 143 units per mg. The molecular weight of the full length α -L-iduronidase of the present invention is about 82,000 daltons comprising about 70,000
25 daltons of amino acids and 12,000 daltons of carbohydrates. The recombinant enzyme of the present invention is endocytosed even more efficiently than has been previously reported for a partially purified preparation of urinary enzyme. The recombinant enzyme according to the present invention is effective in reducing the accumulation of radioactive S-labeled GAG in α -L-iduronidase-deficient fibroblasts, indicating that it is transported to
30 lysosomes, the site of GAG storage. The remarkably low concentration of α -L-iduronidase needed for such correction (half-maximal correction at 0.7 pM) may be very important for the success of enzyme replacement therapy.

The human cDNA of α -L-iduronidase predicts a protein of 653 amino acids and an expected molecular weight of 70,000 daltons after signal peptide cleavage. Amino acid sequencing reveals alanine 26 at the N-terminus giving an expected protein of 629 amino acids. Human recombinant α -L-iduronidase has a Histidine at position 8 of the mature protein. The predicted protein sequence comprises six potential N-linked oligosaccharide modification sites. All of these may be modified in the recombinant protein. The third and sixth sites have been demonstrated to contain one or more mannose 6-phosphate residues responsible for high affinity uptake into cells. The following peptide corresponds to Amino Acids 26-45 of Human Recombinant α -L-iduronidase with an N-terminus alanine and the following sequence (SEQ. ID NO. 2):

ala-glu-ala-pro-his-leu-val-his-val-asp-ala-ala-arg-ala-leu-trp-pro-leu-arg-arg

The overexpression of the α -L-iduronidase of the present invention does not result in generalized secretion of other lysosomal enzymes that are dependent on mannose-6-P targeting. The secreted recombinant α -L-iduronidase is similar to normal secreted enzyme in many respects. Its molecular size, found in various determinations to be 77, 82, 84, and 89 kDa, is comparable to 87 kDa, found for urinary corrective factor (Barton *et al.*, *J. Biol. Chem.* 246: 7773-7779 (1971)), and to 76 kDa and 82 kDa, found for enzyme secreted by cultured human fibroblasts (Myerowitz, *et al.*, *J. Biol. Chem.* 256: 3044-3048 (1991); Taylor, *et al.*, *Biochem. J* 274:263-268 (1991)). The differences within and between the studies are attributed to imprecision of the measurements. The pattern of intracellular processing of the recombinant enzyme, a slow decrease in molecular size and the eventual appearance of an additional band smaller by 9 kDa is the same as for the human fibroblast enzyme. This faster band arises by proteolytic cleavage of 80 N-terminal amino acids.


In a fifth aspect, the present invention features a novel method to purify α -L-iduronidase. In preferred embodiments, the present invention features a method to purify recombinant α -L-iduronidase that has been optimized to produce a rapid and efficient purification with validatable chromatography resins and easy load, wash and elute operation. The method of purifying α -L-iduronidase of the present invention involves a series of column chromatography steps, which allow the high yield purification of enzyme from protein-free production medium. Specifically, Concanavalin A-Sepharose, Heparin-Sepharose and Sephacryl 200 columns were replaced with Blue-Sepharose and Copper chelating columns to increase the capacity of a large-scale purification process, to

reduce leachables and to improve the purity of the product. Concanavalin A lectin is often used to bind enzyme in an initial purification step in the prior published study, and is a protein lectin derived from plants. Concanavalin A is known to leach from columns and contaminate lysosomal enzyme preparations. Such leaching could cause activation of T cells in treated patients and hence is deemed inappropriate for human administration (Furbish, *et al.*, *Proc. Natl. Acad. Sci. USA* 74: 3560-3563 (1977)). Thus, the use of Concanavalin A is avoided in the present purification scheme. In a prior study, the human liver α -L-iduronidase could not be recovered from phenyl columns without high concentrations of detergent (1% Triton X100) denaturation. Hence, a phenyl column was not used in a published purification scheme of this enzyme (Clements, *et al.*, *Eur. J. Biochem.* 152: 21-28 (1985)). The endogenous human liver enzyme is highly modified within the lysosomes by hydrolases which remove sialic acid and phosphate residues and proteases which nick the enzyme. In contrast, the overexpression of recombinant α -L-iduronidase causes 50% of the enzyme to be secreted rather than transported to the lysosome (Zhao, *et al.*, *J. Biol. Chem.* 272: 22758-22765 (1997)). Hence, recombinant iduronidase will have a full array of sialic acid and phosphate residues, which lead to a higher degree of water solubility and lower affinity to the phenyl column. The increased hydrophilicity allows the enzyme to be eluted under non-denaturing conditions using the low salt solutions of around 150-700 mM NaCl. This feature of the recombinant enzyme allows it to be purified in large scale without the use of detergents.

Recombinant α -L-iduronidase over-expressed in a Chinese Hamster Ovary (CHO) cell line, has been purified to near homogeneity following a 3-step column chromatography process. The first column involves an affinity chromatography step using Blue Sepharose 6 FF. The Blue Sepharose 6 FF eluate is then further purified by another affinity chromatography step using Cu^{++} Chelating Sepharose FF. The final polish of the highly purified enzyme is achieved by hydrophobic interaction chromatography using Phenyl Sepharose High Performance (HP). The over-all yield ranges from 45 to 55 percent and the purity of the final product is > 99%. The process is robust, reproducible, and scalable for large-scale manufacturing. The purified enzyme has been characterized with respect to its enzymatic activity using a fluorescence-based substrate, and its functional uptake by fibroblast cells. The enzyme has also been characterized for substrate specificity, carbohydrate profiles, and isoelectric focusing (IEF) profiles.

Particularly preferred embodiments of the method for purifying α -L-iduronidase according to the present invention feature more than one or all of the optimizations according to the following particular embodiments. The purification method of the present invention may therefore provide a purified α -L-iduronidase having the characteristics described herein.

Outline of the α -L-Iduronidase Purification Process



10 1. pH Adjustment/Filtration: The pH of filtered harvest fluid (HF) is adjusted to 5.3 with 1 M H₃PO₄ and then filtered through a 0.45 μ filter (e.g. Sartoclean, Sartorius).

 2. Blue Sepharose FF chromatography: This affinity chromatography step serves to capture iduronidase to reduce the volume and to purify iduronidase by approximately seven to ten fold.

- | | | |
|----|-----------------------|---|
| 15 | Loading capacity: | 4 mg/ml (total protein per ml of resin) |
| | Equilibration buffer: | 10 mM NaPO ₄ , pH 5.3 |
| | Wash buffer: | 400 mM NaCl, 10 mM NaPO ₄ , pH 5.3 |
| | Elution buffer: | 0.8 M NaCl, 10 mM NaPO ₄ , pH 5.3 |
| 20 | Regeneration buffer: | 2 M NaCl, 10 mM NaPO ₄ , pH 5.3 |

Fold of purification: 7-10

Yield: 70-85%

3. Cu^{++} Chelating Sepharose FF chromatography: The Cu^{++} Chelating affinity chromatography step is very effective for removing some contaminating CHO proteins. The inclusion of 10% glycerol in all the buffers seems to be crucial for the quantitative recovery of iduronidase.

Loading capacity: 2 mg/ml

Equilibration buffer: 1 M NaCl, 25 mM NaAc, pH 6.0, 10% Glycerol

Wash buffer: 1 M NaCl, 25 mM NaAc, pH 4.0, 10% Glycerol

10 Elution buffer: 1 M NaCl, 25 mM NaAc, pH 3.7, 10% Glycerol

Regeneration buffer: 1 M NaCl, 50 mM EDTA, pH 8.0

Fold of purification: 2-5

Yield: 80%

4. Phenyl Sephrose HP chromatography: Phenyl Sephrose is used as the last step to further purify the product as well as to reduce residual leached Cibacron blue dye and Cu^{++} ion carried over from previous columns.

Loading capacity: 1 mg/ml

Equilibration buffer: 2 M NaCl, 10 mM NaPO_4 , pH 5.7

Wash buffer: 1.5 M NaCl, 10 mM NaPO_4 , pH 5.7

20 Elution buffer: 0.7 M NaCl, 10 mM NaPO_4 , pH 5.7

Regeneration buffer: 0 M NaCl, 10 mM NaPO_4 , pH 5.7

Fold of purification: 1.5

Yield: 90%

5. Ultrafiltration (UF)/Diafiltration (DF)/Final formulation: The purified iduronidase is concentrated and diafiltered to a final concentration of 1 mg/ml in formulation buffer (150 mM NaCl, 100 mM NaPO_4 , pH 5.8) using a tangential flow filtration (TFF) system (e.g. Sartocoon Slice from Sartorius). The enzyme is then sterilized by filtering through a 0.2-micron filter (e.g., cellulose acetate or polysulfone) and filled into sterile vials.

30 6. Characterization of Purified Iduronidase: Analysis of enzyme purity using SDS-PAGE stained with Coomassie Blue or Silver and Western blot analysis. Analysis of enzymatic activity using 4MU-sulfate as substrate. Analysis of functional uptake using fibroblast cell assay. Analysis of carbohydrates by FACE. Analysis of IEF profiles.

Enzyme purified in this manner has been shown to contain mannose-6-phosphate residues of sufficient quantity at positions 3 and 6 of the N-linked sugars to give the enzyme uptake affinity of less than 30 units per ml (less than 2 nM) enzyme. The enzyme is substantially corrective for glycosaminoglycan storage disorders caused by iduronidase deficiency and has a half-life inside cells of approximately 5 days.

Prior α -L-iduronidase purification schemes (Kakkis, *et al.*, *Protein Expr. Purif.* 5: 225-232 (1994); Kakkis, *et al.*, *Biochem. Mol. Med.* 58: 156-167 (1996); U.S. Patent Application Nos. 09/078,209 and 09/170,977) produced degrees of purity between 90% and less than 99%, which is not optimal for long-term human administration (See FIGURE 12). (These and all other U.S. patents herein are specifically incorporated herein by reference in their entirety.) Treatment with human recombinant α -L-iduronidase with a minimum purity of 97% was associated with some clinical reactions, specifically hives in 5 patients, and complement activation in 4 patients. All patients demonstrated a reaction to a protein that is a trace contaminant to the α -L-iduronidase. (FIGURE 2) Because this protein exists in both the final product and in the serum-free blank CHO cell line supernatant, the extraneous protein most likely originates from the CHO cell. The common proteins that appear to be activating the clinical allergic response are approximately 60kDaltons and 50kDaltons respectively, which are too small to be recombinant human iduronidase. Four patients developed an immune reaction to α -L-iduronidase at least transiently as well as to the Chinese hamster ovary cell host proteins. It is clear that even though the enzyme used to treat patients is highly purified, the degree of purification is important in reducing the immune response to contaminants. FIGURE 2 (SDS-PAGE) and FIGURE 12 (CHOP assay) demonstrate that α -L-iduronidase produced and purified by the production/purification scheme of the present invention has a higher degree of purity and lower degree of CHOP contamination in comparison to that of prior methods of production/purification. Thus, a greater than 97% purity is adequate for patient use, higher levels of purity are desirable and preferable. As shown in FIGURE 12, the optimized purification scheme described above achieves a degree of purity that is greater than 99% and importantly reduces Chinese hamster ovary cell host proteins to less than 1 percent, as determined by the Chinese Hamster Ovary Protein (CHOP) assay.

In a sixth aspect, the present invention features novel methods of treating diseases caused all or in part by a deficiency in α -L-iduronidase. Recombinant α -L-iduronidase provides enzyme replacement therapy in a canine model of MPS 1. This canine model is

deficient in α -L-iduronidase due to a genetic mutation and is similar to human MPS 1. Purified, properly processed α -L-iduronidase was administered intravenously to 11 dogs. In those dogs treated with weekly doses of 25,000 to 125,000 units per kg for 0.5, 3, 6 or 13 months, the enzyme was taken up in a variety of tissues and decreased the lysosomal storage in many tissues. The long term treatment of the disease was associated with clinical improvement in demeanor, joint stiffness, coat and growth. Higher doses of therapy (125,000 units per kg per week) result in better efficacy, including normalization of urinary GAG excretion in addition to more rapid clinical improvement in demeanor, joint stiffness and coat.

10 Enzyme therapy at even small doses of 25,000 units (0.1 mg/kg/wk) resulted in significant enzyme distribution to some tissues and decreases in GAG storage. If continued for over 1 year, some clinical effects were evident in terms of increased activity, size and overall appearance of health. The therapy at this dose did not improve other tissues that are important sites for disease in this entity such as cartilage and brain. Higher doses of 125,000 units (0.5 mg/kg) given 5 times over two weeks demonstrate that improved tissue penetration can be achieved, and a therapeutic effect at the tissue level was accomplished in as little as 2 weeks. Studies at this increased dose have been completed in two dogs for 15 months. These MPS I dogs are showing significant clinical improvement and substantial decreases in urinary GAG excretion into the near normal range. Other than an immune reaction controlled by altered administration techniques, the enzyme therapy has not shown significant clinical or biochemical toxicity. Enzyme therapy at this higher weekly dose is effective at improving some clinical features of MPS I and decreasing storage without significant toxicity.

In a seventh aspect, the present invention features novel pharmaceutical compositions comprising human α -L-iduronidase useful for treating a deficiency in α -L-iduronidase. The recombinant enzyme may be administered in a number of ways such as parenteral, topical, intranasal, inhalation or oral administration. Another aspect of the invention is to provide for the administration of the enzyme by formulating it with a pharmaceutically acceptable carrier, which may be solid, semi-solid, liquid, or an ingestible capsule. Examples of pharmaceutical compositions include tablets, drops such as nasal drops, compositions for topical application such as ointments, jellies, creams and suspensions, aerosols for inhalation, nasal spray, and liposomes. Usually the recombinant enzyme comprises between 0.01 and 99% or between 0.01 and 99% by weight of the

composition, for example, between 0.01 and 20% for compositions intended for injection and between 0.1 and 50% for compositions intended for oral administration.

To produce pharmaceutical compositions in this form of dosage units for oral application containing a therapeutic enzyme, the enzyme may be mixed with a solid, pulverulent carrier, for example lactose, saccharose, sorbitol, mannitol, a starch such as potato starch, corn starch, amylopectin, laminaria powder or citrus pulp powder, a cellulose derivative or gelatin and also may include lubricants such as magnesium or calcium stearate or a Carbowax® or other polyethylene glycol waxes and compressed to form tablets or cores for dragees. If dragees are required, the cores may be coated for example with concentrated sugar solutions which may contain gum arabic, talc and/or titanium dioxide, or alternatively with a film forming agent dissolved in easily volatile organic solvents or mixtures of organic solvents. Dyestuffs can be added to these coatings, for example, to distinguish between different contents of active substance. For the composition of soft gelatin capsules consisting of gelatin and, for example, glycerol as a plasticizer, or similar closed capsules, the active substance may be admixed with a Carbowax® or a suitable oil, *e.g.*, sesame oil, olive oil, or arachis oil. Hard gelatin capsules may contain granulates of the active substance with solid, pulverulent carriers such as lactose, saccharose, sorbitol, mannitol, starches such as potato starch, corn starch or amylopectin, cellulose derivatives or gelatin, and may also include magnesium stearate or stearic acid as lubricants.

Therapeutic enzymes of the subject invention may also be administered parenterally such as by subcutaneous, intramuscular or intravenous injection or by sustained release subcutaneous implant. In subcutaneous, intramuscular and intravenous injection, the therapeutic enzyme (the active ingredient) may be dissolved or dispersed in a liquid carrier vehicle. For parenteral administration, the active material may be suitably admixed with an acceptable vehicle, preferably of the vegetable oil variety such as peanut oil, cottonseed oil and the like. Other parenteral vehicles such as organic compositions using solketal, glycerol, formal, and aqueous parenteral formulations may also be used.

For parenteral application by injection, compositions may comprise an aqueous solution of a water soluble pharmaceutically acceptable salt of the active acids according to the invention, desirably in a concentration of 0.01-10%, and optionally also a stabilizing agent and/or buffer substances in aqueous solution. Dosage units of the solution may advantageously be enclosed in ampules.

When therapeutic enzymes are administered in the form of a subcutaneous implant, the compound is suspended or dissolved in a slowly dispersed material known to those skilled in the art, or administered in a device which slowly releases the active material through the use of a constant driving force such as an osmotic pump. In such cases, administration over an extended period of time is possible.

For topical application, the pharmaceutical compositions are suitably in the form of an ointment, gel, suspension, cream or the like. The amount of active substance may vary, for example, between 0.05- 20% by weight of the active substance. Such pharmaceutical compositions for topical application may be prepared in known manner by mixing the active substance with known carrier materials such as isopropanol, glycerol, paraffin, stearyl alcohol, polyethylene glycol, etc. The pharmaceutically acceptable carrier may also include a known chemical absorption promoter. Examples of absorption promoters are, *e.g.*, dimethylacetamide (U.S. Patent No. 3,472,931), trichloro ethanol or trifluoroethanol (U.S. Patent No. 3,891,757), certain alcohols and mixtures thereof (British Patent No. 1,001,949). A carrier material for topical application to unbroken skin is also described in the British patent specification No. 1,464,975, which discloses a carrier material consisting of a solvent comprising 40-70% (v/v) isopropanol and 0-60% (v/v) glycerol, the balance, if any, being an inert constituent of a diluent not exceeding 40% of the total volume of solvent.

The dosage at which the therapeutic enzyme containing pharmaceutical compositions are administered may vary within a wide range and will depend on various factors such as the severity of the disease, the age of the patient, etc., and may have to be individually adjusted. A possible range for the amount of therapeutic enzyme which may be administered per day is about 0.1 mg to about 2000 mg or about 1 mg to about 2000 mg.

The pharmaceutical compositions containing the therapeutic enzyme may suitably be formulated so that they provide doses within these ranges, either as single dosage units or as multiple dosage units. In addition to containing a therapeutic enzyme (or therapeutic enzymes), the subject formulations may contain one or more substrates or cofactors for the reaction catalyzed by the therapeutic enzyme in the compositions. Therapeutic enzymes containing compositions may also contain more than one therapeutic enzyme.

The recombinant enzyme employed in the subject methods and compositions may also be administered by means of transforming patient cells with nucleic acids encoding

the recombinant α -L-iduronidase. The nucleic acid sequence so encoded may be incorporated into a vector for transformation into cells of the subject to be treated. Preferred embodiments of such vectors are described herein. The vector may be designed so as to integrate into the chromosomes of the subject, *e.g.*, retroviral vectors, or to replicate autonomously in the host cells. Vectors containing encoding α -L-iduronidase nucleotide sequences may be designed so as to provide for continuous or regulated expression of the enzyme. Additionally, the genetic vector encoding the enzyme may be designed so as to stably integrate into the cell genome or to only be present transiently. The general methodology of conventional genetic therapy may be applied to polynucleotide sequences encoding α -L-iduronidase. Conventional genetic therapy techniques have been extensively reviewed. (Friedman, *Science* 244:1275-1281 (1989); Ledley, J. *Inherit. Metab. Dis.* 13:587-616 (1990); Tososhev, *et al.*, *Curr Opinions Biotech.* 1:55-61 (1990)).

A particularly preferred method of administering the recombinant enzyme is intravenously. A particularly preferred composition comprises recombinant α -L-iduronidase, normal saline, phosphate buffer to maintain the pH at about 5.8 and human albumin. These ingredients may be provided in the following amounts:

α -L-iduronidase	0.05-0.2 mg/mL or 12,500-50,000 units per mL
Sodium chloride solution	150 mM in an IV bag, 50-250 cc total volume
Sodium phosphate buffer	10-50 mM, pH 5.8
Human albumin	1 mg/mL

The invention having been described, the following examples are offered to illustrate the subject invention by way of illustration, not by way of limitation.

EXAMPLE 1Producing Recombinant α -L-Iduronidase

Standard techniques such as those described by Sambrook, *et al* (*Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1987)) may be used to clone cDNA encoding human α -L-iduronidase. The human α -L-iduronidase cDNA previously cloned was subcloned into PRCCMV (Invitrogen) as a HindIII-XbaI fragment from a bluescript KS subclone. An intron cassette derived from the murine immunoglobulin Cot intron between exons 2 and 3 was constructed using PCR amplification of bases 788-1372 (Tucker, *et al.*, *Proc. Natl. Acad. Sci. USA* 78: 7684-7688 (1991) of clone pRIR14.5 (Kakkis, *et al.*, *Nucleic Acids Res.* 16:7796 (1988)). The cassette included 136 bp of the 3' end of exon 2 and 242 bp of the 5' end of exon 3, which would remain in the properly spliced cDNA. No ATG sequences are present in the coding region of the intron cassette. The intron cassette was cloned into the HindIII site 5' of the α -L-iduronidase cDNA. The neo gene was deleted by digestion with XhoI followed by recircularizing the vector to make pCMVhldu.

One vial of the working cell bank is thawed and placed in three T225 flasks in DME/F12 or PF-CHO plus supplements, plus 5% FBS and 500 μ g/ml G418. After 2-5 days, the cells are passaged using trypsin-EDTA to a 1-liter spinner flask in the same medium for 2-5 days. The cells are then transferred to two 3-liter spinner flasks for 2-5 days, followed by four 8-liter spinner flasks for 2-5 days. The inoculum from the 8-liter spinner flasks is added to two 110-liter Applikon® stirred tank bioreactors with an 80-90 liter working volume. Macroporous cellulose microcarriers are added at 2 grams per liter (160 grams), with PF-CHO or DME/F12 plus supplements, 5% FBS and 500 μ g/ml of G418 at a final volume of 80-90 liters. The flask is stirred by an overhead drive with a marine impeller. The culture is monitored for agitation speed, temperature, DO and pH probes and controlled the Applikon® control system with a PC interface. The parameters are controlled at the set points or range, 35-37° C depending on culture conditions, 40% air saturation, and pH 6.95, using a heating blanket, oxygen sparger and base pump. The culture is incubated for 3-5 days at which time the culture is emerging from the log phase growth at 1-3 x 10⁶ cells per ml. Thereafter, perfusion is initiated at an increasing rate with PF-CHO medium (with custom modifications, JRH Biosciences). The first four

days of collection (range of 3-5 days) are set aside as "washout." The collection thereafter is the beginning of the production run. Production continues with medium changes of as much as 2-3.5 culture volumes per day for 20-36 days. The culture may be extended for 40 days or longer. The culture is monitored for temperature, pH and DO on a continuous basis. The purification of the enzyme proceeds as described above.

5 Collected production medium containing iduronidase is then acidified to pH 5.3, filtered through a 0.2-micron filter and purified using Blue-Sepharose chromatography. The purified enzyme from multiple rounds of Blue-Sepharose chromatography are then pooled and applied to a copper chelating column and eluted with glycerol in the buffer at a pH of 3.7. The enzyme is held at the acidic pH to inactivate potential viruses. The

10 copper column eluate is then adjusted to pH 5.7 and 2 M NaCl and loaded on the phenyl Sepharose column. The enzyme is eluted at 0.7 M NaCl. The eluate is concentrated and diafiltered into a formulation buffer of 150 mM NaCl, 100 mM NaPO₄, pH5.8. The enzyme is filtered through a 40 nM filter to remove potential viruses and the filtrate

15 adjusted to 0.001% polysorbate 80. The formulated enzyme is sterilely bulk filled into sterile polyethylene containers. The bulk enzyme is then filtered and filled into 5 cc Type 1 glass vials appropriate for injectable pharmaceuticals, stoppered and capped.

EXAMPLE 2

For bioreactors using single cell suspensions, the seed train is prepared as described above in EXAMPLE 1. Using a single cell suspension simplifies bioreactor

20 preparation and inoculation. The bioreactor is inoculated with cells in DMEM/F12 medium (25% of reactor volume) and JRH 325 modified (25% of reactor volume). Medium equal to 50% of the working reactor volume is added over 48 hours. Perfusion (and harvest) is started when cell density reaches 1.0×10^6 and the perfusion medium is the

25 same as described above.

EXAMPLE 3

Short-term intravenous administration of purified human recombinant α -L-iduronidase to 9 MPS I dogs and 6 MPS I cats has shown significant uptake of an enzyme in a variety of tissues with an estimated 50% or more recovery in tissues 24 hours after a

30 single dose. Although liver and spleen take up the largest amount of enzymes, and have the best pathologic improvement, improvements in pathology and glycosaminoglycan content has been observed in many, but not all tissues. In particular, the cartilage, brain and heart valve did not have significant improvement. Clinical improvement was

observed in a single dog on long-term treatment for 13 months, but other studies have been limited to 6 months or less. All dogs, and most cats, that received recombinant human enzyme developed antibodies to the human product. The IgG antibodies are of the complement activating type (probable canine IgG equivalent). This phenomena is also
5 observed in at least 13% of alglucerase-treated Gaucher patients. Proteinuria has been observed in one dog which may be related to immune complex disease. No other effects of the antibodies have been observed in the other treated animals. Specific toxicity was not observed and clinical laboratory studies (complete blood counts, electrolytes, BLJN/creatinine, liver enzymes, urinalysis) have been otherwise normal.

10 Enzyme therapy at even small doses of 25,000 units (0.1 mg/kg/wk) resulted in significant enzyme distribution to some tissues and decreases in GAG storage. If continued for over 1 year, significant clinical effects of the therapy were evident in terms of activity, size and overall appearance of health. The therapy at this dose did not improve other tissues that are important sites for disease in this entity such as cartilage
15 and brain. Higher doses of 125,000 units (0.5 mg/kg) given 5 times over two weeks demonstrate that improved tissue penetration can be achieved and a therapeutic effect at the tissue level was accomplished in as little as 2 weeks. Studies at this increased dose are ongoing in two dogs for six months to date. These MPS I dogs are showing significant clinical improvement and substantial decreases in urinary GAG excretion into
20 the normal range. Other than an immune reaction controlled by altered administration techniques, the enzyme therapy has not shown significant clinical or biochemical toxicity. Enzyme therapy at this higher weekly dose is effective at improving some clinical features of MPS I and decreasing storage without significant toxicity.

25 The results of these various studies in MPS I dogs and one study in MPS I cats show that human recombinant α -L-iduronidase is safe. Although these same results provide significant rationale that this recombinant enzyme should be effective in treating α -L-iduronidase deficiency, they do not predict the clinical benefits or the potential immunological risks of enzyme therapy in humans.

EXAMPLE 4

The human cDNA of α -L-iduronidase predicts a protein of 653 amino acids and an expected molecular weight of 70,000 daltons after signal peptide cleavage. Amino acid sequencing reveals alanine 26 at the N-terminus giving an expected protein of 629 amino acids. Human recombinant α -L-iduronidase has a Histidine at position 8 of the mature protein. The predicted protein sequence comprises six potential N-linked oligosaccharide modification sites. All of these sites are modified in the recombinant protein. The third and sixth sites have been demonstrated to contain one or more mannose 6-phosphate residues responsible for high affinity uptake into cells.

This peptide corresponds to Amino Acids 26-45 of Human Recombinant α -L-iduronidase with an N-terminus alanine and the following sequence (SEQ ID NO. 2):
ala-glu-ala-pro-his-leu-val-his-val-asp-ala-ala-arg-ala-leu-trp-pro-leu-arg-arg

The recombinant enzyme has an apparent molecular weight of 82,000 daltons on SDS-PAGE due to carbohydrate modifications. Purified human recombinant α -L-iduronidase has been sequenced by the UCLA Protein Sequencing facility. It is preferred to administer the recombinant enzyme intravenously. Human recombinant α -L-iduronidase was supplied for the clinical trial in 10 mL polypropylene vials at a concentration of 100,000-200,000 units per mL. The final dosage form of the enzyme used in the clinical trial includes human recombinant α -L-iduronidase, normal saline, and 100 mM phosphate buffer at pH 5.8. These are prepared in a bag of normal saline. Polysorbate 80 at a final concentration of 0.001 % was added to the formulation to stabilize the protein against shear, thereby avoiding precipitation in the final product vials.

Final Vial Formulation Currently in Use

<u>Component</u>	<u>Composition</u>
α -L-iduronidase	Target to 0.7 mg/mL or 100 (new) units per mL
5 Sodium chloride solution	150 mM
Sodium phosphate buffer	100 mM, pH 5.8
Polysorbate 80	0.001%

Final Dosage Form Used in the Treatment of Patients

<u>Component</u>	<u>Composition</u>
10 α -L-iduronidase product	5-12 fold dilution of vial concentration
Sodium chloride solution	50 mM Sodium phosphate buffer 100-250 cc IV bag
Human albumin	1 mg/ml

15

EXAMPLE 5Effects of Intravenous Administration of α -L-Iduronidase
in Patients with Mucopolysaccharidosis I

Based on studies of cloning of cDNA encoding α -L-iduronidase (Scott, *et al.*, *Proc. Natl. Acad. Sci. USA* 88: 9695-99 (1991); Stoltzfus, *et al.*, *J. Biol. Chem.* 267: 6570-75 (1992)) and animal studies showing effects of α -L-iduronidase to reduce lysosomal storage in many tissues (Shull, *et al.*, *Proc. Natl. Acad. Sci. USA* 91: 12937-41 (1994); Kakkis, *et al.*, *Biochem. Mol. Med.* 58: 156-67 (1996)), a 52-week study was conducted to assess the safety and clinical efficacy of intravenous administration of highly purified α -L-iduronidase in ten patients with mucopolysaccharidosis I (MPS I).

25 Recombinant human α -L-iduronidase was produced and purified to greater than 97-99%. Patients demonstrated typical clinical manifestations of the disorder and diagnosis was confirmed by biochemical determination of α -L-iduronidase deficiency in leukocytes.

30 Patients were given recombinant human α -L-iduronidase (diluted in normal saline with 0.1% human serum albumin) intravenously at a dose of 125,000 units per kg (using original assay and unit definition); 3,000 units per kg were given over the first hour, and 61,000 units per kg in each of the following two hours. The dose of 125,000 units per kg

is equivalent to 100 SI units per kg using the new assay. The infusions were prolonged up to 4-6 hours in patients who had hypersensitivity reactions.

At baseline and at 6, 12, 26 and 52 weeks depending on the evaluation, the patients underwent examinations including history, physical examinations by specialists, 5 echocardiography, EKG, MRI, polysomnography (weeks 0 and 26), skeletal survey (weeks 0, 26, 52), range of motion measurements, corneal photographs, and skin biopsy (week 0) to set up fibroblast cultures for enzyme determination and genotyping. Range of motion measurements were performed with a goniometer and the maximum active (patient initiated) range was recorded for each motion. Shoulder flexion is movement of 10 the elbow anteriorly from the side of the body and elbow and knee extension represent straightening of the joint. Degrees of restriction represent the difference between the normal maximum range of motion for age and the measured value. Polysomnography was performed according to American Thoracic Society guidelines and apneic events (cessation of oro-nasal airflow for 10 seconds or more), hypopneic events (decreased oro- 15 nasal airflow of 50% or more with desaturation of 2% or more, or evidence of arousal), minutes below 89% oxygen saturation and total sleep time recorded among the standard measurements required. From these data an apnea/hypopnea index was calculated by dividing the total number of apneic and hypopneic events by the number of hours of sleep. Biochemical studies included measurement of enzyme activity in leukocytes and 20 brushings of buccal mucosal, urinary glycosaminoglycan levels, and tests for serum antibodies to recombinant human α -L-iduronidase (ELISA and Western blot). Organ volumes were determined by analysis of MRI digital image data using Advantage Windows workstation software from General Electric. The organ volume was measured in milliliters and was converted to weight assuming a density of 1 gram per ml. Urinary 25 glycosaminoglycan excretion was assayed by an adaptation of a published method. Western blots and ELISA assays for antibodies to recombinant human α -L-iduronidase were performed by standard methods. Uronic acids and N-sulfate of urinary glycosaminoglycans were analyzed by the orcinol, carbazole and MBTH methods, and by electrophoretic separations.

30 All patients received weekly infusions of recombinant human α -L-iduronidase administered for 52 weeks. The mean activity of α -L-iduronidase in leukocytes was 0.04 units per mg before treatment and when measured on average 7 days after an infusion (i.e. immediately before the next infusion), 4.98 units per mg, or 15.0 percent of normal.

Enzyme activity was not detectable in buccal brushings prior to treatment, but 7 days after infusions it reached a level of 1 percent of normal.

Liver volume decreased by 19 to 37 percent from baseline in 9 patients and 5 percent in one patient at 52 weeks; the mean decrease was 25.0 percent ($n=10$, $P<0.001$).
5 By 26 weeks, liver size was normal for body weight and age in 8 patients (Figure 1). In 2 patients (patients 6 and 9) with the largest relative liver size at baseline, liver size was close to normal at 52 weeks (3.2 and 3.3 percent of body weight, respectively). Spleen size decreased in 8 patients by 13 to 42 percent from baseline (mean decrease of 20 percent in 10 patients, $P<0.001$).

10 Urinary glycosaminoglycan excretion declined rapidly by 3 to 4 weeks and by 8-12 weeks had fallen by 60-80 percent of baseline. At 52 weeks, the mean reduction was 63 percent (range 53-74; $p<0.001$). Eight of ten patients had a 75 percent or greater reduction of the baseline amount of urinary glycosaminoglycan in excess of the upper limit of normal for age. The results were confirmed by assay of uronic acids and N-
15 sulfate (a test specific for heparan sulfate). Electrophoresis studies of urine detected a significant reduction in heparan sulfate and dermatan sulfate excretion but some excess dermatan sulfate excretion persisted in all patients.

The mean height increased 6.0 cm (5.2 percent) in the 6 prepubertal patients (Table 2) and their mean height growth velocity increased from 2.8 cm/yr to 5.2 cm/yr
20 during treatment ($P=0.011$). For all 10 patients, mean body weight increased 3.2 kg (8.8 percent) and the mean increase was 4.2 kg (17.1 percent) for the 6 prepubertal patients (Table 2). In these 6 patients, the mean pretreatment weight growth velocity increased from 1.7 kg per year to 3.8 kg per year during treatment ($P=0.04$).

Shoulder flexion (moving the elbow anteriorly) increased in 6 of the 8 subjects
25 evaluated at baseline with a mean improvement for the right and left shoulders of 28° and 26°, respectively ($P < 0.002$; Figure 2). Elbow extension and knee extension increased by a mean of 7.0° ($P < 0.03$) and 3.2° ($P=0.10$), respectively, in the 10 patients (Figure 2).

Analysis of the improvement in individual patients revealed that the most restricted joints had the greatest improvement. For example at baseline, patients 5, 9 and
30 10 could not flex their shoulders (move the elbow anteriorly) beyond 100°, which increased 21° to 51° after treatment. Similarly, patients 2 and 9 had a substantial increase in knee extension. The changes in range of motion were accompanied by patient-reported increases in physical activities such as being able to wash their hair, hold a hamburger normally, hang from monkey bars, and play sports better.

Seven patients had a decrease in apnea and hypopnea events from 155 to 60 per night upon treatment (a 61 percent decrease) with a change in mean apnea/hypopnea index (total number of events per hour) from 2.1 to 1.0. Three patients had clinically significant sleep apnea and all three improved during treatment. In patient 2, the apnea/hypopnea index decreased from 4.5 at baseline to 0.4 at 26 weeks and total time of oxygen desaturation decreased from 48 minutes to 1 minute per night. Patient 6 required nightly continuous positive airway pressure therapy before treatment due to severe desaturation (61 minutes below 89 percent saturation with continuous positive airway pressure in 368 minutes of sleep), but by 52 weeks, the patient tolerated the sleep study without CPAP and desaturated below 89 percent for only 8 minutes during 332 minutes of sleep. Patient 9 had an apnea hypopnea index of 9.5 which decreased to 4.0 by 26 weeks. Patient 8 worsened with an apnea hypopnea index of 0.1 increasing to 3.1 at 26 weeks and 9.3 at 52 weeks for unclear reasons. Eight of ten patients or their families reported improved breathing, and 5 of 7 noted quieter nighttime breathing, improved sleep quality and decreased daytime somnolence.

New York Heart Association functional classification was determined by serial patient interviews. All 10 patients reported improvement by one or two classes but there was no significant objective data from echocardiographic studies to verify direct cardiac benefit. The improved functional scores may reflect improvements in other aspects of MPS I disease rather than cardiac function. Comparing baseline to 52 weeks of treatment, echocardiography demonstrated decreased tricuspid regurgitation or pulmonic regurgitation in 4 patients but two patients (patients 2 and 7) had worsening mitral regurgitation. At baseline, patient 6 had atrial flutter and clinical signs of cardiac failure including dyspnea at rest and peripheral edema. By 12 weeks, he had normal sinus rhythm with first degree block and his dyspnea at rest and pitting edema resolved.

All 10 patients reported a lack of endurance and limitations of daily activities before treatment but exercise tolerance was not formally tested. During treatment, all patients improved and by 26 weeks, many were able to walk more, run and play sports. Patients 3, 4 and 5 reported the resolution of severe incapacitating headaches after treatment for 6-12 weeks.

Several patients reported decreased photophobia or conjunctival irritation. Visual acuity improved in one patient (20/1000 to 20/200 in one eye) and modestly in 2 others.

The results of this study indicate that intravenous administration of the highly purified recombinant human α -L-iduronidase of the present invention results in clinical

and biochemical improvement in patients with Mucopolysaccharidosis I. The normalization of liver size and near normalization of urinary glycosaminoglycan excretion is consistent with data from studies in dogs with Mucopolysaccharidosis I, which demonstrated clearance of storage in the liver and decreased urinary
5 glycosaminoglycan excretion in as little as 2 weeks.

Hypersensitivity reactions to the infusions of recombinant human α -L-iduronidase were less severe than predicted from studies in dogs. Though important in some patients, recurrent urticaria was manageable with premedication and adjustments in infusion rate. Antibodies specific to α -L-iduronidase were detected in 4 patients with usually
10 subclinical complement activation, and both the antibodies and complement activation declined with time. Similar IgG-mediated immune responses have been previously noted in patients with Gaucher disease treat with glucocerebrosidase, although the events were more frequent in our patients. Mucopolysaccharidosis I patients with a null genotype may have a greater immune response than in these 10 patients, none of whom has a null.

15 Thus, recombinant human α -L-iduronidase can reduce lysosomal storage and ameliorates some aspects of clinical disease of Mucopolysaccharidosis I.

The invention, and the manner and process of making and using it, are now described in such full, clear, concise and exact terms as to enable any person skilled in the art to which it pertains, to make and use the same. It is to be understood that the
20 foregoing describes preferred embodiments of the present invention and that modifications may be made therein without departing from the spirit or scope of the present invention as set forth in the claims. To particularly point out and distinctly claim the subject matter regarded as invention, the following claims conclude this specification.

WHAT IS CLAIMED IS:

1. A recombinant α -L-iduronidase enzyme or biologically active fragments or mutant thereof with a purity of equal to or greater than 99%.
- 5 2. The recombinant α -L-iduronidase enzyme or biologically active fragments or mutant thereof of Claim 1 with a specific activity greater than about 240,000 units per milligram protein.
3. A formulation of a pharmaceutical composition comprising said human recombinant α -L-iduronidase or biologically active fragments or mutant thereof alone of
10 Claim 1 or in combination with a pharmaceutically suitable carrier.
4. The pharmaceutical composition of claim 3 further comprising a sodium chloride solution, a buffer and polysorbate 80.
5. The pharmaceutical composition of claim 3 wherein said human recombinant α -L-iduronidase is present at a concentration of about 0.5 mg/mL and about
15 125,000 units per mL.
6. The pharmaceutical composition of claim 4 wherein said sodium chloride solution is at a concentration of about 150 mM.
7. The pharmaceutical composition of claim 4 wherein said buffer is a sodium phosphate buffer at a concentration of about 100 mM, and pH 5.4-5.9.
- 20 8. The pharmaceutical composition of claim 4 after dilution into the dosage form wherein said human albumin is present at a concentration of at least about 1 mg/mL.
9. The pharmaceutical composition of Claim 8 wherein human albumin is used to prevent or reduce acute allergic or complement mediated reactions in said human subject.
- 25 10. The pharmaceutical solution of claim 4 wherein the pH of said solution is maintained at about 5.8.

11. The pharmaceutical composition of claim 4 wherein said polysorbate 80 is maintained at 0.001%.

12. The pharmaceutical composition of claim 11 wherein said polysorbate is required to stabilize the protein in the final product.

5 13. A method of producing human α -L-iduronidase of Claim 1, comprising the steps of:

(a) preparing a seed train of cells transformed with nucleic acids encoding for inoculation into a bioreactor;

(b) preparing a mixture containing macroporous microcarriers by
10 washing and autoclaving said microcarriers in phosphate buffered saline, combining said microcarriers with growth medium and fetal bovine serum, and pumping said microcarrier mixture into said bioreactor;

(c) inoculating and incubating said cells in said bioreactor under control of pH, dissolved oxygen and perfusion; and

15 (d) harvesting cells when cell density reaches about 10^6 .

14. A method of preparing seed train of said cells of Claim 6 for mass production, comprising:

(a) washing and resuspending an aliquot of working cell bank CHO cells 2.131 in culture medium containing protein-free medium with supplementation of
20 7.6 mg/L thymidine, 13.6 mg/L hypoxanthine, 375 μ g/mL G418 and 5% fetal bovine serum;

(b) incubating said cell suspension for two to three days at 37°C and 5% carbon dioxide in three 225 cm-flasks;

(c) splitting said cell suspension by adding the cells sequentially to one
25 1-liter spinner flask, two 3-liter flasks, and four 8-liter flasks;

(d) rotating said cell suspension at 50 revolutions per minute, followed by increasing inoculum volume by incubating and subculturing cells to a final cell density of about 2.0×10^5 to 2.5×10^5 .

15 15. A method of purifying of α -L-iduronidase of Claim 1 to equal to or greater than about 99% purity, comprising the steps of:

(a) harvesting and filtering fluid obtained from a culture of cells transformed with nucleic acids encoding said human α -L-iduronidase;

(b) adjusting the pH of the fluid to an acidic pH, followed by filtration through a 0.2 micron to 0.54 micron filter;

10 (c) passing the fluid through a blue sepharose FF column to capture said human recombinant α -L-iduronidase;

(d) passing the fluid through a copper chelating sepharose column to remove contaminating CHO proteins;

15 (e) passing the fluid through a phenyl sepharose column to reduce residual leached Cibacron blue dye and copper ions carried over from previous columns; and

(f) concentrating and diafiltering the purified α -L-iduronidase.

16 16. The method of Claim 4, wherein said blue sepharose FF column is used to purify said human α -L-iduronidase seven to ten fold.

20 17. The method of Claim 4, wherein said method comprises using 10% glycerol in all buffers to increase the quantitative recovery of said human α -L-iduronidase.

18. A method of treating diseases caused all or in part by a deficiency in α -L-iduronidase, comprising the steps of:

25 (a) administering said formulation of Claim 3 to a human subject in need thereof; and

(b) optimizing said treatment by evaluating biochemical and clinical symptoms of said subject through routine assessment of history, physical examination, echocardiography, electrocardiography, magnetic resonance imaging, polysomnography, skeletal survey, range of motion measurements, corneal photographs, and skin biopsy.

5 19. The method of Claim 18 wherein the disease is mucopolysaccharidosis.

 20. The method of Claim 18 wherein the disease is MPS I.

 21. The method of Claim 18 wherein the disease is selected from the group consisting of: Hurler's disease, Scheie syndrome and Hurler-Scheie syndrome.

 22. The method of Claim 18 wherein said subject suffering from the disease
10 demonstrates about 1% or less of a normal α -L-iduronidase activity.

 23. The method of Claim 18 wherein a dose of at least about 125,000 units or 0.5 mg/kg of said human recombinant α -L-iduronidase is administered weekly to a patient suffering from a deficiency thereof.

 24. The method of Claim 18 wherein said administering is the slow infusion of
15 at least 0.5 mg/kg of said formulation for about an hour, followed by a rapid two-hour infusion rate.

 25. The method of Claim 24 wherein said infusion is used to minimize complement mediation clinical allergic reactions.

 26. The method of Claim 18 wherein treatment with human recombinant α -L-
20 iduronidase reduces lysosomal storage.

 27. The method of Claim 18 wherein treatment causes improvement in said clinical and biochemical symptoms of said human subjects.

 28. The method of Claim 24 wherein said treatment results in normalization of
25 liver volume and urinary glycosaminoglycan excretion, reduction in spleen size and apnea/hypopnea events, increase in height and growth velocity in prepubertal patients, improvement in shoulder flexion and elbow and knee extension, improvement in symptoms related to cardiac function, and improvement in endurance and limitations of daily activities.

```

      10      20      30      40      50      60      70
      * *      * *      * *      * *      * *      * *      * *
GACGGATCGG GAGATCTCCC GATCCCCTAT GGTGACTCT CAGTACAATC TGCTCTGATG CCGCATAGTT

      80      90      100      110      120      130      140
      * *      * *      * *      * *      * *      * *      * *
AAGCCAGTAT CTGCTCCCTG CTTGTGTGTT GGAGGTGCGT GAGTAGTGCG CGAGCAAAT TTAAGCTACA

      150      160      170      180      190      200      210
      * *      * *      * *      * *      * *      * *      * *
ACAAGGCAAG GCTTGACCGA CAATTGCATG AAGAATCTGC TTAGGTTAG GCGTTTTGCG CTGCTTCGCG

      220      230      240      250      260      270      280
      * *      * *      * *      * *      * *      * *      * *
ATGTACGGGC CAGATATACG CGTTGACATT GATTATTGAC TAGTTATTAA TAGTAATCAA TTACGGGGTC

      290      300      310      320      330      340      350
      * *      * *      * *      * *      * *      * *      * *
ATTAGTTCAT AGCCCATATA TGGAGTTCGG CGTTACATAA CTTACGGTAA ATGGCCC GCC TGGCTGACCG

      360      370      380      390      400      410      420
      * *      * *      * *      * *      * *      * *      * *
CCCAACGACC CCGGCCCAT T GACGTC AATA ATGACGTATG TTCCCATAGT AACGCCAATA GGGACTTTCC

      430      440      450      460      470      480      490
      * *      * *      * *      * *      * *      * *      * *
ATTGACGTCA ATGGGTGGAC TATTTACGGT AAAC TGCCCA CTTGGCAGTA CATCAAGTGT ATCATATGCC

      500      510      520      530      540      550      560
      * *      * *      * *      * *      * *      * *      * *
AAGTACGCCC CCTATTGACG TCAATGACGG TAAATGGCCC GCCTGGCATT ATGCCAGTA CATGACCTTA

      570      580      590      600      610      620      630
      * *      * *      * *      * *      * *      * *      * *
TGGGACTTTC CTACTTGGCA GTACATCTAC GTATTAGTCA TCGCTATTAC CATGGTGATG CGGTTTTGGC

      640      650      660      670      680      690      700
      * *      * *      * *      * *      * *      * *      * *
AGTACATCAA TGGGCGTGG A TAGCGTTTG ACTCACGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA

      710      720      730      740      750      760      770
      * *      * *      * *      * *      * *      * *      * *
TGGGAGTTTG TTTTGGCACC AAAATCAACG GGA CTTTCCA AAATGTCGTA ACAACTCCGC CCCATTGACG

      780      790      800      810      820      830      840
      * *      * *      * *      * *      * *      * *      * *
CAAATGGGCG GTAGGCGTGT ACGGTGGGAG GTCTATATAA GCAGAGCTCT CTGGCTRACT AGAGAACCCA

      850      860      870      880      890      900      910
      * *      * *      * *      * *      * *      * *      * *
CTGCTTAACT GGCTTATCGA AATTAATACG ACTCACTATA GGGAGACCCA AGCTTCGCAG AATTCCTGCG

      920      930      940      950      960      970      980
      * *      * *      * *      * *      * *      * *      * *
GCTGCTACAG TGTGTCCAGC GTCCTGCCTG GCTGIGCTGA GUGCTGGAAC AGTGGCGCAT CATTCAAGTG

      990      1000      1010      1020      1030      1040      1050
      * *      * *      * *      * *      * *      * *      * *
CACAGTTACC CATCCTGAGT CTGGCACCTT AACTGGCACA ATTGCCAAG TCACAGGTGA GCTCAGATGC
    
```

FIGURE 1

```

1060      1070      1080      1090      1100      1110      1120
* * * * *
ATACCAGGAC AATTGTATGAC GTTCCCTGCT CACATGCCTG CTTTCTTCCT ATAATACAGA TGCTCAACTA

1130      1140      1150      1160      1170      1180      1190
* * * * *
ACTGCTCATG TCCTTATATC ACAGAGGGAA ATTGGAGCTA TCTGAGGAAC TGCCCAGAAG GGAAGGGCAG

1200      1210      1220      1230      1240      1250      1260
* * * * *
AGGGGTCTTG CTCTCCTTGT CTGAGCCATA ACTCTTCTTT CTACCTTCCA GTGAACACCT TCCCACCCCA

1270      1280      1290      1300      1310      1320      1330
* * * * *
GGTCCACCTG CTACCGCCGC CGTCGGAGGA GCTGGCCCTG AATGAGCTCT TGTCCCTGAC ATGCCTGGTG

1340      1350      1360      1370      1380      1390      1400
* * * * *
CGAGCTTCA ACCCTAAAGA AGTGCTGGTG CGATGGCTGC ATGGAAATGA GGAGCTGTCC CCAGAAAGCT

1410      1420      1430      1440      1450      1460      1470
* * * * *
ACCTAGTGTT TGAGCCCCTA AAGGAGCCAG GCGAGGGAGC CACCACCTAC CTGGTGACAA GGGTGTGCG

1480      1490      1500      1510      1520      1530      1540
* * * * *
TGTATCAGCT GAAAGCTTGA TATCGAATTC CGGAGGCGGA ACCGGCAGTG CAGCCCGAAG CCCCAGTC

1550      1560      1570      1580      1590
* * * * *
CCCCGAGCAG CGTGGCC ATG CGT CCC CTG CGC CCC CGC GCC GCG CTG CTG GCG CTC CTG
Met Arg Pro Leu Arg Pro Arg Ala Ala Leu Leu Ala Leu Leu>
a a a a a ORF RF[1] a a a a a >

1600      1610      1620      1630      1640      1650
* * * * *
GCC TCG CTC CTG GCC GCG CCC CCG GTG GCC CCG GCC GAG GCC CCG CAC CTG GTG CAT
Ala Ser Leu Leu Ala Ala Pro Pro Val Ala Pro Ala Glu Ala Pro His Leu Val His>
a a a a a a a a a a a ORF RF[1] a a a a a a a a a a a >

1660      1670      1680      1690      1700      1710
* * * * *
GTG GAC GCG GCC CGC GCG CTG TGG CCC CTG CGG CGC TTC TGG AGG AGC ACA GGC TTC
Val Asp Ala Ala Arg Ala Leu Trp Pro Leu Arg Arg Phe Trp Arg Ser Thr Gly Phe>
a a a a a a a a a a a ORF RF[1] a a a a a a a a a a a >

1720      1730      1740      1750      1760      1770
* * * * *
TGC CCG CCG CTG CCA CAC AGC CAG GCT GAC CAG TAC GTC CTC AGC TGG GAC CAG CAG
Cys Pro Pro Leu Pro His Ser Gln Ala Asp Gln Tyr Val Leu Ser Trp Asp Gln Gln>
a a a a a a a a a a a ORF RF[1] a a a a a a a a a a a >

1780      1790      1800      1810      1820
* * * * *
CTC AAC CTC GCC TAT GTG GGC GCC GTC CCT CAC CGC GGC ATC AAG CAG GTC CCG ACC
Leu Asn Leu Ala Tyr Val Gly Ala Val Pro His Arg Gly Ile Lys Gln Val Arg Thr>
a a a a a a a a a a a ORF RF[1] a a a a a a a a a a a >

1830      1840      1850      1860      1870      1880
* * * * *
CAC TGG CTG CTG GAG CTT GTC ACC ACC AGG GGG TCC ACT GGA CGG GGC CTG AGC TAC
His Trp Leu Leu Glu Leu Val Thr Thr Arg Gly Ser Thr Gly Arg Gly Leu Ser Tyr>

```

FIGURE 1A


```

AAAAAAAAA AAAAAAAG AATTCCTGCA GCCCGGGGA TCCACTAGTT CTAGAGGGCC CGTTTAAACC
    3760      3770      3780      3790      3800      3810      3820
    *  *      *  *      *  *      *  *      *  *      *  *      *  *
CGCTGATCAG CCTCGACTGT GCCTTCTAGT TGCCAGCCAT CTGTTGTTTG CCCCTCCCC GTGCCCTCCT

    3830      3840      3850      3860      3870      3880      3890
    *  *      *  *      *  *      *  *      *  *      *  *      *  *
TGACCCTGGA AGGTGCCACT CCCACTGTCC TTTCTAATA AAATGAGGAA ATTGCATCGC ATTGTCTGAG

    3900      3910      3920      3930      3940      3950      3960
    *  *      *  *      *  *      *  *      *  *      *  *      *  *
TAGGTGTCAT TCTATTCTGG GGGGTGGGGT GGGGCAGGAC AGCAAGGGGG AGGATTGGGA AGACAATAGC

    3970      3980      3990      4000      4010      4020      4030
    *  *      *  *      *  *      *  *      *  *      *  *      *  *
AGGCATGCTG GGGATGCGGT GGGCTCTATG GCTTCTGAGG CGGAAAGAAC CAGCTGGGGC TCGAGAGCTT

    4040      4050      4060      4070      4080      4090      4100
    *  *      *  *      *  *      *  *      *  *      *  *      *  *
GGCGTAATCA TGGTCATAGC TGTTCCTGT  GTGAAATTGT TATCCGCTCA CAATTCCACA CAACATACGA

    4110      4120      4130      4140      4150      4160      4170
    *  *      *  *      *  *      *  *      *  *      *  *      *  *
GCCGGAAGCA TAAAGTGTA  AGCCTGGGGT GCCTAATGAG TGAGCTAACT CACATTAATT GCGTTGCGCT

    4180      4190      4200      4210      4220      4230      4240
    *  *      *  *      *  *      *  *      *  *      *  *      *  *
CACTGCCCGC TTTCCAGTCG GGAAACCTGT CGTGCCAGCT GCATTAATGA ATCGGCCAAC GCGCGGGGAG

    4250      4260      4270      4280      4290      4300      4310
    *  *      *  *      *  *      *  *      *  *      *  *      *  *
AGCGGTTTTG CGTATTGGGC GCTCTCCGC TTCTCTGCTC ACTGACTCGC TGCGCTCGGT CTTCCGGCTG

    4320      4330      4340      4350      4360      4370      4380
    *  *      *  *      *  *      *  *      *  *      *  *      *  *
CGGGCAGCGG TATCAGCTCA CTCAAAGGCG GTAATACGGT TATCCACAGA ATCAGGGGAT AACGCAGGAA

    4390      4400      4410      4420      4430      4440      4450
    *  *      *  *      *  *      *  *      *  *      *  *      *  *
AGAACATGTG AGCAAAGGC CAGCAAAGG CCAGGAACCG TAAAAAGGCC GCGTTGCTGG CGTTTTTCCA

    4460      4470      4480      4490      4500      4510      4520
    *  *      *  *      *  *      *  *      *  *      *  *      *  *
TAGGCTCCGC CCCCTGACG AGCATCACAA AAATCGACGC TCAAGTCAGA GGTGGCGAAA CCCGACAGGA

    4530      4540      4550      4560      4570      4580      4590
    *  *      *  *      *  *      *  *      *  *      *  *      *  *
CTATAAAGAT ACCAGGCGTT TCCCCTGGA AGCTCCCTCG TGCGCTCTCC TGTTCCGACC CTGCCGCTTA

    4600      4610      4620      4630      4640      4650      4660
    *  *      *  *      *  *      *  *      *  *      *  *      *  *
CCGGATACCT GTCCGCCTTT CTCCCTTCGG GAAGCGTGCC GCTTCTCAA TGCTCAGCT GTAGGTATCT

    4670      4680      4690      4700      4710      4720      4730
    *  *      *  *      *  *      *  *      *  *      *  *      *  *
CAGTTCEGTG TAGGTGCTTC GCTCCAAGCT GGGCTGTGTG CACGAACCCC CCGTTCAGCC CGACCGCTGC

    4740      4750      4760      4770      4780      4790      4800
    *  *      *  *      *  *      *  *      *  *      *  *      *  *
GCCTTATCCG GTAACATCG TCTTGAGTCC AACCCGGTAA GACACGACTT ATCGCCACTG GCAGCAGCCA
    
```

FIGURE 1E

```

      4810      1820      4830      4840      4850      4860      4870
      * *      * *      * *      * *      * *      * *      * *
CTGGTACACAG GATTAGCAGA GCGAGGTATG TAGGCGGTGC TACAGAGTTC TTGAAGTGGT GGCCTAACTA

      4880      4890      4900      4910      4920      4930      4940
      * *      * *      * *      * *      * *      * *      * *
CGGCTACACT AGAAGGACAG TATTTGGTAT CTGCGCTCTG CTGAAGCCAG TTACCTTCGG AAAAAGAGTT

      4950      4960      4970      4980      4990      5000      5010
      * *      * *      * *      * *      * *      * *      * *
GGTAGCTCTT GATCCGGCAA ACAAACCACC GCTGGTAGCG GTGGTTTTTT TGTTTGCAAG CAGCAGATTA

      5020      5030      5040      5050      5060      5070      5080
      * *      * *      * *      * *      * *      * *      * *
CGCGCAGAAA AAAAGGATCT CAAGAAGATC CTTGATCTT TTCTACGGG TCTGACGCTC AGTGAACGA

      5090      5100      5110      5120      5130      5140      5150
      * *      * *      * *      * *      * *      * *      * *
AAACTCACGT TAAGGGATTT TGGTCATGAG ATTATCAAAA AGGATCTTCA CCTAGATCCT TTTAAATTAA

      5160      5170      5180      5190      5200      5210      5220
      * *      * *      * *      * *      * *      * *      * *
AAATGAAGTT TTAAATCAAT CTAAAGTATA TATGAGTAAA CTTGGTCTGA CAGTTACCAA TGCTTAATCA

      5230      5240      5250      5260      5270      5280      5290
      * *      * *      * *      * *      * *      * *      * *
GTGAGGCACC TATCTCAGCG ATCTGTCTAT TTCGTTTCATC CATAGTTGCC TGACTCCCCG TCGTGTAGAT

      5300      5310      5320      5330      5340      5350      5360
      * *      * *      * *      * *      * *      * *      * *
AACTACGATA CGGGAGGGCT TACCATCTGG CCCAGTGCT GCAATGATAC CGCGAGACCC ACGCTCACCG

      5370      5380      5390      5400      5410      5420      5430
      * *      * *      * *      * *      * *      * *      * *
GCTCCAGATT TATCAGCAAT AAACCAGCCA GCCGGAAGGG CCGAGCGCAG AAGTGGTCCT GCAACTTTAT

      5440      5450      5460      5470      5480      5490      5500
      * *      * *      * *      * *      * *      * *      * *
CCGCCTCCAT CCAGTCTATT AATTGTTGCC GGAAGCTAG AGTAAGTAGT TCGCCAGTTA ATAGTTTGGC

      5510      5520      5530      5540      5550      5560      5570
      * *      * *      * *      * *      * *      * *      * *
CAACGTTGTT GCCATTGCTA CAGGCATCGT GGTGTCACGC TCGTCGTTTG GTATGGCTTC ATTCAGCTCC

      5580      5590      5600      5610      5620      5630      5640
      * *      * *      * *      * *      * *      * *      * *
GGTTCCCAAC GATCAAGGCG AGTTACATGA TCCCCATGT TGTGCAAAA AGCGGTTAGC TCCTTCGGTC

      5650      5660      5670      5680      5690      5700      5710
      * *      * *      * *      * *      * *      * *      * *
CTCCGATCGT TGTCAGAAGT AAGTTGGCCG CAGTGTTATC ACTCATGGTT ATGGCAGCAC TGCATARTTC

      5720      5730      5740      5750      5760      5770      5780
      * *      * *      * *      * *      * *      * *      * *
TCTTACTGTC ATGCCATCCG TAAGATGCTT TTCTGTGACT GGTGAGTACT CAACCAAGTC ATTCTGAGAA

      5790      5800      5810      5820      5830      5840      5850
      * *      * *      * *      * *      * *      * *      * *
TAGTGTATGC GCGGACCGAG TTGCTCTTGC CCGGCTCAA TACGGGATAA TACCGCGCCA CATAGCAGAA

      5860      5870      5880      5890      5900      5910      5920
      * *      * *      * *      * *      * *      * *      * *

```

FIGURE 1F


```

CTTTAAAAGT GCTCATT GGA AACGTT CTTCGGGGCG AAAACTCTCA AGGATCTTAC CGCTGTTGAG
      5930      5940      5950      5960      5970      5980      5990
      * *      * *      * *      * *      * *      * *      * *
ATCCAGTTCG ATGTAACCCA CTCGTGCACC CAACTGATCT TCAGCATCTT TTACTTTCAC CAGCGTTTCT
      6000      6010      6020      6030      6040      6050      6060
      * *      * *      * *      * *      * *      * *      * *
GGGTGAGCAA AAACAGGAAG GCAAAATGCC GCAAAAAGG GAATAAGGGC GACACGGAAA TGTGAATAC
      6070      6080      6090      6100      6110      6120      6130
      * *      * *      * *      * *      * *      * *      * *
TCATACTCTT CCTTTTCAA TATTATTGAA GCATTTATCA GGGTTATTGT CTCATGAGCG GATACATATT
      6140      6150      6160      6170      6180      6190      6200
      * *      * *      * *      * *      * *      * *      * *
TGAATGTATT TAGAAAATA AACAAATAGG GGTTCGCGC ACATTCCCC GAAAAGTGCC ACCTGACGTC
    
```


FIGURE 1G

FIGURE 2. SDS-POLYACRYLAMIDE GELS DEMONSTRATING IMPROVEMENTS IN PURITY

Gel using the Kakkis et al 1994, published procedure for purification



Gel using the new Galli Process contained in this application



1. Molecular Weight Marker
2. Prior Process Carson (nonpublished) Batch 2000C9001 Reference Reduced (7.5 µg)
3. Same Batch 2000C9001 Reference Reduced (5.0 µg)
4. Galli Process Enzyme Batch P10006 (5.0 µg)

FIGURE 3A IDURONIDASE PRODUCTION USING THE GALLI PROCESS





FIGURE 3B. IDURONIDASE PRODUCTION USING BUTYRATE INDUCTION



Reduction in Liver Volume During Enzyme Therapy




Figure 4

Urinary GAG Excretion During Enzyme Therapy




Figure 5




Figure 6

Shoulder flexion to 104 weeks in four patients with most restriction






Figure 7

Sleep Apnea Improves




0 weeks



After
6 weeks

Figure 8

Apneas + Hypopneas During Sleep Pre and Post Treatment



JOM001 AHC002 RCD003 SSH004 SWD005 GMD006 JAN007 N-M008 CEL009 BBG010

Figure 9

Pulmonary Function Tests in GMD006




Figure 10

Increased Height Growth Velocity




Figure 11

FIGURE 12.**COMPARISON OF HOST PROTEIN CONTAMINATION BETWEEN A PRIOR AND THE NEW GALLI PROCESS****Chinese Hamster Ovary Host Protein Contamination by ELISA Assay**

SOURCE AND BATCH NUMBER	CHOP PROTEIN CONTAMINATION (microgram per milligram)	PERCENT CHOP CONTAMINATION	PURITY OF THE ENZYME FROM CHOP
Prior Process (Carson/REI)			
C9002	14	1.4%	98.6%
C9003	24	2.4%	97.6%
C9004	16	1.6%	98.4%
New Process (Galli)			
P1003	<1.3	<0.13%	>99.9%
P1006	1.2	0.12%	99.9%
P1007	<0.6	<0.06%	>99.9%
P1008	<0.67	<0.067%	>99.9%

SEQUENCE LISTING

<110> BIOMARIN PHARMACEUTICALS
HARBOR-UCLA REI

<120> RECOMBINANT ALPHA-L-IDURONIDASE, METHODS FOR PRODUCING
AND PURIFYING THE SAME AND METHODS FOR TREATING DISEASES CAUSED BY
DEFICIENCIES THEREOF

<130> 00800005100PC00

<140> TO BE ASSIGNED

<141> TO BE ASSIGNED

<150> 09/439,923

<151> 1999-11-12

<160> 2

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 6200

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1558)...(3510)

<400> 1

gacggatcgg	gagatctccc	gatcccctat	ggtcagactct	cagtacaatc	tgctctgatg	60
ccgcatagtt	aagccagtat	ctgctccctg	cttgtgtgtt	ggaggctcgt	gagtagtgcg	120
cgagcaaat	ttaagctaca	acaaggcaag	gcttgaccga	caattgcatg	agaatctgc	180
ttagggtag	gcgttttgcg	ctgcttcgcg	atgtaooggc	cagatatacg	cgttgacatt	240
gattattgac	tagttattaa	tagtaatcaa	ttacggggtc	attagttcat	agccatata	300
tggagtccg	cgttacataa	cttacggtaa	atggcccgcc	tggtgaccg	cccaacgacc	360
cccgccatt	gacgtcaata	atgacgtatg	ttcccatagt	aacgccaata	gggactttcc	420
attgacgtca	atgggtggac	tatttacggg	aaactgcccc	cttggcagta	catcaagtgt	480
atcatatgcc	aagtagcccc	cctattgacg	tcaatgacgg	taaattggccc	gcctggcatt	540
atgccagta	catgacctta	tgggactttc	ctacttggca	gtacatctac	gtattagtca	600
tcgctattac	catgggtgatg	cggttttggc	agtacatcaa	tgggcgtgga	tagcggtttg	660
actcacgggg	atttccaagt	ctccaccccc	ttgacgtcaa	tgggagtttg	ttttggcacc	720
aaaatcaacg	ggactttcca	aaatgtcgtg	acaactccgc	cccattgacg	caaatgggcg	780
gtaggcgtgt	acgggtggag	gtctatataa	gcagagctct	ctggctaact	agagaaccca	840
ctgcttaact	ggcttatcga	aattaatacg	actcaactata	gggagaccca	agcttcgcag	900
aattcctgcg	gctgctacag	tgtgtccagc	gtcctgcctg	gctgtgctga	gcgctggaac	960
agtggcgcag	cattcaagtg	cacagttacc	catcctgagt	ctggcacctt	aactggcaca	1020
attgccaaag	tcacaggtga	gctcagatgc	ataccaggac	attgtatgac	gttcctctgt	1080
cacatgctg	ctttcttctt	ataatacaga	tgctcaacta	actgctcatg	tccttatatc	1140
acagagggaa	attggagcta	tctgaggaac	tgcccagaag	ggaagggcag	aggggtcttg	1200
ctctccttgt	ctgagccata	actcttcttt	ctaccttcca	gtgaacacct	tcccacccca	1260
ggtccacctg	ctaccgccgc	cgtcggagga	gctggcccctg	aatgagctct	tgctcctgac	1320
atgctgggtg	cgagctttca	accctaaaga	agtgcctggtg	cgatggctgc	atggaaatga	1380
ggagctgtcc	ccagaaagct	acctagtgtt	tgagccccta	aaggagccag	gcgaggggagc	1440

caccacctac ctggtgacaa gcgtgttgcg tgtatcagct gaaagcttga tatkgaattc 1500
 cggaggcggg accggcagtg cagcccgaag cccgcagtc cccgagcacg cgtggcc atg 1560
 Met
 1

cg tcc ctg cgc ccc cgc gcc gcg ctg ctg gcg ctc ctg gcc tcg ctc 1608
 Arg Pro Leu Arg Pro Arg Ala Ala Leu Leu Ala Leu Leu Ala Ser Leu
 5 10 15

ctg gcc gcg ccc ccg gtg gcc ccg gcc gag gcc ccg cac ctg gtg cat 1656
 Leu Ala Ala Pro Pro Val Ala Pro Ala Glu Ala Pro His Leu Val His
 20 25 30

gtg gac gcg gcc cgc gcg ctg tgg ccc ctg cgg cgc ttc tgg agg agc 1704
 Val Asp Ala Ala Arg Ala Leu Trp Pro Leu Arg Arg Phe Trp Arg Ser
 35 40 45

aca gcc ttc tgc ccc ccg ctg cca cac agc cag gct gac cag tac gtg 1752
 Thr Gly Phe Cys Pro Pro Leu Pro His Ser Gln Ala Asp Gln Tyr Val
 50 55 60 65

ctc agc tgg gac cag cag ctc aac ctc gcc tat gtg ggc gcc gtc cct 1800
 Leu Ser Trp Asp Gln Gln Leu Asn Leu Ala Tyr Val Gly Ala Val Pro
 70 75 80

cac cgc ggc atc aag cag gtc cgg acc cac tgg ctg ctg gag ctt gtc 1848
 His Arg Gly Ile Lys Gln Val Arg Thr His Trp Leu Leu Glu Leu Val
 85 90 95

acc acc agg ggg tcc act gga cgg gcc ctg agc tac aac ttc acc cac 1896
 Thr Thr Arg Gly Ser Thr Gly Arg Gly Leu Ser Tyr Asn Phe Thr His
 100 105 110

ctg gac ggg tac ctg gac ctt ctc agg gag aac cag ctc ggg ttt gag 1944
 Leu Asp Gly Tyr Leu Asp Leu Leu Arg Glu Asn Gln Leu Gly Phe Glu
 115 120 125

ctg atg ggc agc gcc tcg ggc cac ttc act gac ttt gag gac aag cag 1992
 Leu Met Gly Ser Ala Ser Gly His Phe Thr Asp Phe Glu Asp Lys Gln
 130 135 140 145

cag gtg ttt gag tgg aag gac ttg gtc tcc agc ctg gcc agg aga tac 2040
 Gln Val Phe Glu Trp Lys Asp Leu Val Ser Ser Leu Ala Arg Arg Tyr
 150 155 160

atc ggt agg tac gga ctg gcg cat gtt tcc aag tgg aac ttc gag acg 2088
 Ile Gly Arg Tyr Gly Leu Ala His Val Ser Lys Trp Asn Phe Glu Thr
 165 170 175

tgg aat gag cca gac cac cac gac ttt gac aac gtc tcc atg acc atg 2136
 Trp Asn Glu Pro Asp His His Asp Phe Asp Asn Val Ser Met Thr Met
 180 185 190

caa gcc ttc ctg aac tac tac gat gcc tgc tcg gag ggt ctg cgc gcc 2184
 Gln Gly Phe Leu Asn Tyr Tyr Asp Ala Cys Ser Glu Gly Leu Arg Ala
 195 200 205

gcc agc ccc gcc ctg cgg ctg gga ggc ccc ggc gac tcc ttc cac acc 2232
 Ala Ser Pro Ala Leu Arg Leu Gly Gly Pro Gly Asp Ser Phe His Thr
 210 215 220 225

cca ccg cga tcc ccg ctg agc tgg ggc ctc ctg cgc cac tgc cac gac 2280
 Pro Pro Arg Ser Pro Leu Ser Trp Gly Leu Leu Arg His Cys His Asp
 230 235 240

ggc acc aac ttc ttc act ggg gag gcg ggc gtg cgg ctg gac tac atc 2328
 Gly Thr Asn Phe Phe Thr Gly Glu Ala Gly Val Arg Leu Asp Tyr Ile
 245 250 255

tcc ctc cac agg aag ggt gcg cgc agc tcc atc tcc atc ctg gag cag 2376
 Ser Leu His Arg Lys Gly Ala Arg Ser Ser Ile Ser Ile Leu Glu Gln
 260 265 270

gag aag gtc gtc gcg cag cag atc cgg cag ctc ttc ccc aag ttc gcg 2424
 Glu Lys Val Val Ala Gln Gln Ile Arg Gln Leu Phe Pro Lys Phe Ala
 275 280 285

gac acc ccc att tac aac gac gag gcg gac ccg ctg gtg ggc tgg tcc 2472
 Asp Thr Pro Ile Tyr Asn Asp Glu Ala Asp Pro Leu Val Gly Trp Ser
 290 295 300 305

ctg cca cag ccg tgg agg gcg gac gtg acc tac gcg gcc atg gtg gtg 2520
 Leu Pro Gln Pro Trp Arg Ala Asp Val Thr Tyr Ala Ala Met Val Val
 310 315 320

aag gtc atc gcg cag cat cag aac ctg cta ctg gcc aac acc acc tcc 2568
 Lys Val Ile Ala Gln His Gln Asn Leu Leu Leu Ala Asn Thr Thr Ser
 325 330 335

gcc ttc ccc tac gcg ctc ctg agc aac gac aat gcc ttc ctg agc tac 2616
 Ala Phe Pro Tyr Ala Leu Leu Ser Asn Asp Asn Ala Phe Leu Ser Tyr
 340 345 350

cac ccg cac ccc ttc gcg cag cgc acg ctc acc gcg cgc ttc cag gtc 2664
 His Pro His Pro Phe Ala Gln Arg Thr Leu Thr Ala Arg Phe Gln Val
 355 360 365

aac aac acc cgc ccg ccg cac gtg cag ctg ttg cgc aag ccg gtg ctc 2712
 Asn Asn Thr Arg Pro Pro His Val Gln Leu Leu Arg Lys Pro Val Leu
 370 375 380 385

acg gcc atg ggg ctg ctg gcg ctg ctg gat gag gag cag ctc tgg gcc 2760
 Thr Ala Met Gly Leu Leu Ala Leu Leu Asp Glu Glu Gln Leu Trp Ala
 390 395 400

gaa gtg tcg cag gcc ggg acc gtc ctg gac agc aac cac acg gtg ggc 2808
 Glu Val Ser Gln Ala Gly Thr Val Leu Asp Ser Asn His Thr Val Gly
 405 410 415

gtc ctg gcc agc gcc cac cgc ccc cag ggc ccg gcc gac gcc tgg cgc 2856
 Val Leu Ala Ser Ala His Arg Pro Gln Gly Pro Ala Asp Ala Trp Arg
 420 425 430

gcc gcg gtg ctg atc tac gcg agc gac gac acc cgc gcc cac ccc aac 2904

Ala	Ala	Val	Leu	Ile	Tyr	Ala	Ser	Asp	Asp	Thr	Arg	Ala	His	Pro	Asn		
	435					440					445						
cgc	agc	gtc	gcg	gtg	acc	ctg	cgg	ctg	cgc	ggg	gtg	ccc	ccc	ggc	ccg	2952	
Arg	Ser	Val	Ala	Val	Thr	Leu	Arg	Leu	Arg	Gly	Val	Pro	Pro	Gly	Pro		
	450				455					460					465		
ggc	ctg	gtc	tac	gtc	acg	cgc	tac	ctg	gac	aac	ggg	ctc	tgc	agc	ccc	3000	
Gly	Leu	Val	Tyr	Val	Thr	Arg	Tyr	Leu	Asp	Asn	Gly	Leu	Cys	Ser	Pro		
			470						475					480			
gac	ggc	gag	tgg	cgg	cgc	ctg	ggc	cgg	ccc	gtc	ttc	ccc	acg	gca	gag	3048	
Asp	Gly	Glu	Trp	Arg	Arg	Leu	Gly	Arg	Pro	Val	Phe	Pro	Thr	Ala	Glu		
			485					490						495			
cag	ttc	cgg	cgc	tag	cgc	gcg	gct	gag	gac	ccg	gtg	gcc	gcg	gcg	ccc	3096	
Gln	Phe	Arg	Arg	*	Arg	Ala	Ala	Glu	Asp	Pro	Val	Ala	Ala	Ala	Pro		
		500						505						510			
cgc	ccc	tta	ccc	gcc	ggc	ggc	cgc	ctg	agg	ctg	cgc	ccc	gcg	ctg	cgg	3144	
Arg	Pro	Leu	Pro	Ala	Gly	Gly	Arg	Leu	Arg	Leu	Arg	Pro	Ala	Leu	Arg		
		515					520					525					
ctg	ccg	tcg	ctt	ttg	ctg	gtg	cac	gtg	tgt	gcg	cgc	ccc	gag	aag	ccg	3192	
Leu	Pro	Ser	Leu	Leu	Leu	Val	His	Val	Cys	Ala	Arg	Pro	Glu	Lys	Pro		
		530				535					540						
ccc	ggg	cag	gtc	acg	cgg	ctc	cgc	gcc	ctg	ccc	ctg	acc	caa	ggg	cag	3240	
Pro	Gly	Gln	Val	Thr	Arg	Leu	Arg	Ala	Leu	Pro	Leu	Thr	Gln	Gly	Gln		
		545			550					555					560		
ctg	gtt	ctg	gtc	tgg	tcg	gat	gaa	cac	gtg	ggc	tcc	aag	tgc	ctg	tgg	3288	
Leu	Val	Leu	Val	Trp	Ser	Asp	Glu	His	Val	Gly	Ser	Lys	Cys	Leu	Trp		
			565						570					575			
aca	tac	gag	atc	cag	ttc	tct	cag	gac	ggt	aag	gcg	tac	acc	ccg	gtc	3336	
Thr	Tyr	Glu	Ile	Gln	Phe	Ser	Gln	Asp	Gly	Lys	Ala	Tyr	Thr	Pro	Val		
			580					585						590			
agc	agg	aag	cca	tcg	acc	ttc	aac	ctc	ttt	gtg	ttc	agc	cca	gac	aca	3384	
Ser	Arg	Lys	Pro	Ser	Thr	Phe	Asn	Leu	Phe	Val	Phe	Ser	Pro	Asp	Thr		
		595					600					605					
ggt	gct	gtc	tct	ggc	tcc	tac	cga	gtt	cga	gcc	ctg	gac	tac	tgg	gcc	3432	
Gly	Ala	Val	Ser	Gly	Ser	Tyr	Arg	Val	Arg	Ala	Leu	Asp	Tyr	Trp	Ala		
		610				615					620						
cga	cca	ggc	ccc	ttc	tcg	gac	cct	gtg	ccg	tac	ctg	gag	gtc	cct	gtg	3480	
Arg	Pro	Gly	Pro	Phe	Ser	Asp	Pro	Val	Pro	Tyr	Leu	Glu	Val	Pro	Val		
		625			630					635				640			
cca	aga	ggg	ccc	cca	tcc	ccg	ggc	aat	cca	tgagcctgtg	ctgagcccca					3530	
Pro	Arg	Gly	Pro	Pro	Ser	Pro	Gly	Asn	Pro								
			645					650									
gtgggttgca	cctccaccgg	cagtcagcga	gctggggctg	cactgtgccc	atgctgccct											3590	
cccatacccc	cctttgcaat	atatttttat	attttaaaaa	aaaaaaaaaa	aaaaaaaaaa											3650	

```

aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aattcctgca 3710
gccccgggga tccactagtt ctagagggcc cgtttaaacc cgctgatcag cctcgactgt 3770
gccttctagt tgccagccat ctggttgttg cccctcccc gtgccttcct tgaccctgga 3830
aggtgccact cccactgtcc tttcctaata aaatgaggaa attgcatcgc attgtctgag 3890
taggtgtcat tctattctgg ggggtggggt ggggcaggac agcaaggggg aggattggga 3950
agacaatagc aggcattgctg gggatgctgt gggctctatg gcttctgagg cggaaagaac 4010
cagctggggc tcgagagctt ggcgtaatca tggctatagc tgtttcctgt gtgaaattgt 4070
tatccgctca caattccaca caacatacga gccggaagca taaagtgtaa agcctgggggt 4130
gcctaattgag tgagctaact cacattaatt gcgttgcgct cactgcccgc tttccagtcg 4190
ggaaacctgt cgtgccagct gcattaatga atcgccaac gcgcggggag aggcggtttg 4250
cgtattgggc gctcttcgc ttcctcgctc actgactcgc tgcgctcggg cgttcggctg 4310
cggcgagcgg tatcagctca ctcaaaggcg gtaatacggg tatccacaga atcaggggat 4370
aacgcaggaa agaacatgtg agcaaaaggc gccaaaaagg ccaggaaccg taaaaaggcc 4430
gcgttgcctg cgtttttcca taggctccgc cccctgacg agcatcacia aaatcgacgc 4490
tcaagtocaga ggtggcgaaa cccgacagga ctataaagat accaggcggt tccccctgga 4550
agctccctcg tgcgctctcc tgttccgacc ctgcccgtta cgggatacct gtccgccttt 4610
ctcccctcgg gaagcgtggc gctttctcaa tgcctcacgct gtaggtatct cagttcggtg 4670
taggtcgttc gctccaagct gggctgtgtg caogaacccc ccgttcagcc cgaccgctgc 4730
gccttatccg gtaactatcg tcttgagtcc aaccggtaa gacacgactt atcgccactg 4790
gcagcagcca ctggtaacag gattagcaga gcgaggtatg taggcgggtg tacagagttc 4850
ttgaagtggg ggcctaacta oggctacact agaaggacag tatttggtat ctgctctctg 4910
ctgaagccag ttaccttcgg aaaaagagtt ggtagctctt gatccggcaa acaaacacc 4970
gctggtagcg tgggtttttt tgtttgcaag cagcagatta cgcgcagaaa aaaaggatct 5030
caagaagatc ctttgatctt ttctacgggg totgacgctc agtggaacga aaactcaagt 5090
taagggattt tggctatgag attatcaaaa aggatcttca cctagatcct tttaaattaa 5150
aaatgaagtt ttaaataaat ctaaaagtata tatgagtaaa ctgggtctga cagttaccaa 5210
tgcttaatac gtgaggcacc tatctcagcg atctgtctat ttcgttcctc catagttgcc 5270
tgactccccg tcgtgtatag aactacgata cgggagggct taccatctgg cccagtgct 5330
gcaatgatac cgcgagacc acgctcaccg gctccagatt tatcagcaat aaaccagcca 5390
cccggaaggg ccgagcgcag aagtggctct gcaactttat ccgctccat ccagtctatt 5450
aattgttgcc ggggaagctag agtaagttag tcgccagtta atagtttgcg caacgttggt 5510
gccattgcta caggcatcgt ggtgtcacgc tcgctggttg gtatggcttc attcagctcc 5570
ggttcccaac gatcaaggcg agttacatga tccccatgt tgtgcaaaaa agcggttagc 5630
tccttcggtc ctccgatcgt tgtcagaagt aagttggccg cagtgttatc actcatggtt 5690
atggcagcac tgcataatc tcttactgtc atgccatccg taagatgctt ttctgtgact 5750
ggtgagtact caaccaagtc attctgagaa tagtgtatgc ggcgaccgag ttgctcttgc 5810
ccggcgtcaa tacgggataa taccgcgcca catagcagaa ctttaaaagt gctcatcatt 5870
ggaaaacggt cttcggggcg aaaactctca aggatcttac cgctgttgag atccagttcg 5930
atgtaaccca ctcggtgcacc caactgatct tcagcatctt ttactttcac cagcgtttct 5990
gggtgagcaa aaacaggaag gcaaaatgcc gcaaaaaagg gaataagggc gacacggaaa 6050
tgttgaatac tcatactctt cctttttcaa tattattgaa gcatttatca gggttattgt 6110
ctcatgagcg gatacatatt tgaatgtatt tagaaaaata acaaatagg ggttccgcgc 6170
acatttcccc gaaaagtgcc acctgacgct 6200

```

```

<210> 2
<211> 650
<212> PRT
<213> Homo sapiens

```

```

<400> 2
Met Arg Pro Leu Arg Pro Arg Ala Ala Leu Leu Ala Leu Leu Ala Ser
 1           5           10           15
Leu Leu Ala Ala Pro Pro Val Ala Pro Ala Glu Ala Pro His Leu Val
           20           25           30
His Val Asp Ala Ala Arg Ala Leu Trp Pro Leu Arg Arg Phe Trp Arg
           35           40           45
Ser Thr Gly Phe Cys Pro Pro Leu Pro His Ser Gln Ala Asp Gln Tyr

```

50						55						60					
Val	Leu	Ser	Trp	Asp	Gln	Gln	Leu	Asn	Leu	Ala	Tyr	Val	Gly	Ala	Val		
65					70					75					80		
Pro	His	Arg	Gly	Ile	Lys	Gln	Val	Arg	Thr	His	Trp	Leu	Leu	Glu	Leu		
				85					90					95			
Val	Thr	Thr	Arg	Gly	Ser	Thr	Gly	Arg	Gly	Leu	Ser	Tyr	Asn	Phe	Thr		
			100					105					110				
His	Leu	Asp	Gly	Tyr	Leu	Asp	Leu	Leu	Arg	Glu	Asn	Gln	Leu	Gly	Phe		
		115					120					125					
Glu	Leu	Met	Gly	Ser	Ala	Ser	Gly	His	Phe	Thr	Asp	Phe	Glu	Asp	Lys		
		130					135				140						
Gln	Gln	Val	Phe	Glu	Trp	Lys	Asp	Leu	Val	Ser	Ser	Leu	Ala	Arg	Arg		
145					150					155					160		
Tyr	Ile	Gly	Arg	Tyr	Gly	Leu	Ala	His	Val	Ser	Lys	Trp	Asn	Phe	Glu		
				165					170					175			
Thr	Trp	Asn	Glu	Pro	Asp	His	His	Asp	Phe	Asp	Asn	Val	Ser	Met	Thr		
		180						185					190				
Met	Gln	Gly	Phe	Leu	Asn	Tyr	Tyr	Asp	Ala	Cys	Ser	Glu	Gly	Leu	Arg		
		195					200					205					
Ala	Ala	Ser	Pro	Ala	Leu	Arg	Leu	Gly	Gly	Pro	Gly	Asp	Ser	Phe	His		
		210				215					220						
Thr	Pro	Pro	Arg	Ser	Pro	Leu	Ser	Trp	Gly	Leu	Leu	Arg	His	Cys	His		
225					230					235					240		
Asp	Gly	Thr	Asn	Phe	Phe	Thr	Gly	Glu	Ala	Gly	Val	Arg	Leu	Asp	Tyr		
			245						250					255			
Ile	Ser	Leu	His	Arg	Lys	Gly	Ala	Arg	Ser	Ser	Ile	Ser	Ile	Leu	Glu		
		260						265					270				
Gln	Glu	Lys	Val	Val	Ala	Gln	Gln	Ile	Arg	Gln	Leu	Phe	Pro	Lys	Phe		
		275					280					285					
Ala	Asp	Thr	Pro	Ile	Tyr	Asn	Asp	Glu	Ala	Asp	Pro	Leu	Val	Gly	Trp		
		290				295					300						
Ser	Leu	Pro	Gln	Pro	Trp	Arg	Ala	Asp	Val	Thr	Tyr	Ala	Ala	Met	Val		
305					310					315				320			
Val	Lys	Val	Ile	Ala	Gln	His	Gln	Asn	Leu	Leu	Leu	Ala	Asn	Thr	Thr		
			325						330					335			
Ser	Ala	Phe	Pro	Tyr	Ala	Leu	Leu	Ser	Asn	Asp	Asn	Ala	Phe	Leu	Ser		
		340						345					350				
Tyr	His	Pro	His	Pro	Phe	Ala	Gln	Arg	Thr	Leu	Thr	Ala	Arg	Phe	Gln		
		355					360					365					
Val	Asn	Asn	Thr	Arg	Pro	Pro	His	Val	Gln	Leu	Leu	Arg	Lys	Pro	Val		
		370				375					380						
Leu	Thr	Ala	Met	Gly	Leu	Leu	Ala	Leu	Leu	Asp	Glu	Glu	Gln	Leu	Trp		
385					390					395				400			
Ala	Glu	Val	Ser	Gln	Ala	Gly	Thr	Val	Leu	Asp	Ser	Asn	His	Thr	Val		
			405						410					415			
Gly	Val	Leu	Ala	Ser	Ala	His	Arg	Pro	Gln	Gly	Pro	Ala	Asp	Ala	Trp		
		420						425					430				
Arg	Ala	Ala	Val	Leu	Ile	Tyr	Ala	Ser	Asp	Asp	Thr	Arg	Ala	His	Pro		
		435					440					445					
Asn	Arg	Ser	Val	Ala	Val	Thr	Leu	Arg	Leu	Arg	Gly	Val	Pro	Pro	Gly		
		450				455					460						
Pro	Gly	Leu	Val	Tyr	Val	Thr	Arg	Tyr	Leu	Asp	Asn	Gly	Leu	Cys	Ser		
465					470					475				480			
Pro	Asp	Gly	Glu	Trp	Arg	Arg	Leu	Gly	Arg	Pro	Val	Phe	Pro	Thr	Ala		
			485						490				495				
Glu	Gln	Phe	Arg	Arg	Arg	Ala	Ala	Glu	Asp	Pro	Val	Ala	Ala	Ala	Pro		
			500					505					510				

Arg Pro Leu Pro Ala Gly Gly Arg Leu Arg Leu Arg Pro Ala Leu Arg
 515 520 525
 Leu Pro Ser Leu Leu Leu Val His Val Cys Ala Arg Pro Glu Lys Pro
 530 535 540
 Pro Gly Gln Val Thr Arg Leu Arg Ala Leu Pro Leu Thr Gln Gly Gln
 545 550 555 560
 Leu Val Leu Val Trp Ser Asp Glu His Val Gly Ser Lys Cys Leu Trp
 565 570 575
 Thr Tyr Glu Ile Gln Phe Ser Gln Asp Gly Lys Ala Tyr Thr Pro Val
 580 585 590
 Ser Arg Lys Pro Ser Thr Phe Asn Leu Phe Val Phe Ser Pro Asp Thr
 595 600 605
 Gly Ala Val Ser Gly Ser Tyr Arg Val Arg Ala Leu Asp Tyr Trp Ala
 610 615 620
 Arg Pro Gly Pro Phe Ser Asp Pro Val Pro Tyr Leu Glu Val Pro Val
 625 630 635 640
 Pro Arg Gly Pro Pro Ser Pro Gly Asn Pro
 645 650

1

INTERNATIONAL SEARCH REPORT

International Application No
PC 1 / US 00/31293

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12N9/24 A61K38/47 A61P3/00				
According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K C12N				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, BIOSIS, MEDLINE, CHEM ABS Data				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
X	WO 99 58691 A (HARBOR UCLA) 18 November 1999 (1999-11-18)	1-14, 18-28		
Y	the whole document	15-17		
X	--- KAKKIS E D ET AL: "Long-term and high-dose trial of enzyme replacement therpay in the canine model of mucopolysaccharidosis I" BIOCHEMICAL AND MOLECULAR MEDICINE, ORLANDO, FL, US, vol. 58, no. 2, August 1996 (1996-08), pages 156-167, XP000862844	1-14, 18-28		
Y	the whole document	15-17		
	--- -/--			
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.				
° Special categories of cited documents :				
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none; vertical-align: top;"> *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed </td> <td style="width: 50%; border: none; vertical-align: top;"> *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family </td> </tr> </table>			*A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family
A document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family			
Date of the actual completion of the international search	Date of mailing of the international search report			
29 October 2001	07/11/2001			
Name and mailing address of the ISA	Authorized officer			
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Teyssier, B			

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/31293

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	CLEMENTS P R ET AL: "Human alpha-L-iduronidase 1. Purification, monoclonal antibody production, native and subunit molecular mass" EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 152, no. 1, October 1985 (1985-10), pages 21-28, XP000857400 page 22, column 1 ---	15-17
X	UNGER E G ET AL: "Recombinant.alpha.-L-iduronidase: characterization of the purified enzyme and correction of mucopolysaccharidosis type I fibroblasts" BIOCHEMICAL JOURNAL, vol. 304, no. 1, November 1994 (1994-11), pages 43-49, XP000857388 ---	1-14, 18-28
A	the whole document ---	15-17
X	WO 99 51724 A (CORVEN EMILE VAN ;PHARMING INTELLECTUAL PTY BV (NL); WEGGEMAN MIRA) 14 October 1999 (1999-10-14) page 11, line 24 -page 12, line 7 page 26 -page 28 ---	15-17
T	KAKKIS E D ET AL: "Enzyme-replacement therapy in mucopolysaccharidosis I." NEW ENGLAND JOURNAL OF MEDICINE, vol. 344, no. 3, 18 January 2001 (2001-01-18), pages 182-188, XP001030869 the whole document -----	1-12, 18-28

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/31293

Patent document cited in search report	A	Publication date		Patent family member(s)	Publication date
WO 9958691	A	18-11-1999		AU 4072499 A	29-11-1999
				BR 9910323 A	30-01-2001
				CN 1300323 T	20-06-2001
				EP 1078075 A2	28-02-2001
				WO 9958691 A2	18-11-1999
WO 9951724	A	14-10-1999		AU 3522999 A	25-10-1999
				WO 9951724 A1	14-10-1999
				EP 1071756 A1	31-01-2001